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Abstract 
 
The gonadotropin-releasing hormone (GnRH) receptor is a G-protein-coupled receptor in the 
pituitary gonadotropes and is an important control point for reproduction.  GnRH binds to the 
GnRH receptor (GnRHR) resulting in the synthesis and release of follicle stimulating hormone 
(FSH) and luteinizing hormone (LH).  The sensitivity of the pituitary to GnRH can be directly 
correlated with GnRHR levels.  The mouse GnRHR promoter contains three cis elements 
containing binding sites for steroidogenic factor-1 (SF-1), namely site 1 (-15/-7), site 2 (-244/-
236) and site 3 (-304/-296) as well as an activator protein-1 (AP-1)-like consensus sequence 
(TGAGTCA) at position –336/-330.  While sites 1 and 2 and the AP-1 site have been 
previously shown to be involved in regulation of transcription of the mouse GnRHR 
(mGnRHR) promoter in some cell lines, the role of site 3 has not been previously 
investigated.  This study investigated whether transcription of the mGnRHR gene is regulated 
by GnRH and glucocorticoids in the LβT2 gonadotrope pituitary cell line, and the role therein 
of site 3 and the AP-1 site and their cognate proteins, using a combination of in vitro protein-
DNA binding studies and promoter-reporter assays.  The role played by site 3 and the AP-1 
site in basal transcription of the mGnRHR gene in LβT2 cells was the first area of 
investigation during this study. Luciferase reporter plasmids containing 600 bp of the 
mGnRHR promoter were used where the site 3 and AP-1 sites were either wild-type or 
mutated.  Two constructs were prepared from the wild-type construct, i.e. wild type (LG), site 
3 mutant (m3) and AP-1 mutant (mAP-1). Transfection of LG, m3 and mAP-1 plasmids into 
LβT2 cells was carried out to determine the effect of these mutations on the basal expression 
of the mGnRHR gene.  Mutation of site 3 resulted in a 1.5 fold increase in the transcriptional 
activity of the mGnRHR promoter.  This suggests that site 3 plays a role in the inhibition of 
basal transcriptional levels of the mGnRHR promoter in LβT2 cells.  Mutation of the AP-1 site 
resulted in a 50% decrease in basal transcriptional levels of the mGnRHR promoter in LβT2 
cells.  This suggests that the AP-1 site is involved in positively mediating the basal 
transcriptional response of the GnRHR promoter in LβT2 cells.  Experiments towards the 
understanding of the mechanism of the cis elements (site 3 and AP-1 site) on the mGnRHR 
promoter were carried out along with the role of protein kinase A (PKA) pathways, proteins 
involved and the effect of varying doses for varying times of GnRH, as well as the over-
expression of PKA and the SF-1 protein.   It was found that site 3 and the AP-1 site are not 
involved in the GnRH response.  Results suggest that site 3 is partially involved in the PKA 
response in LβT2 cells. Site 3 can bind SF-1 protein as shown via competitive electrophoretic 
mobility shift assays (EMSA).  When EMSA’s were performed on the AP-1 site the findings 
were that the c-Fos protein was not involved in the activation of the AP-1 site. A factor was 
found to bind to the AP-1 site, which did not require the intact AP-1 site, suggesting that it 
could be the c-Jun protein that binds to the AP-1 site under basal conditions.   
Another area that was investigated was whether the mGnRHR promoter can be regulated by 
dexamethasone (dex) either via the AP-1 site or site 3.  A dose and time-dependent increase 
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in promoter activity was observed with dex. This effect appears to require site 3 and the AP-1 
site, as shown by the complete loss of response when these sites were individually mutated, 
consistent with a functional interaction between site 3 and the AP-1 site in LβT2 cells. 
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Opsomming 
 
Die gonadotropienvrystellings hormoon (GnRH) reseptor is ‘n G-proteïen-gekoppelde 
reseptor in die pituitêre gonadotrope en is ’n belangrike beheerpunt vir reproduksie. GnRH 
bind aan die GnRH reseptor (GnRHR) met die gevolg dat follikel stimulerende hormoon 
(FSH) en luteïeniserende (LH) gesintetiseer en vrygestel word. Die sensitiwiteit van die 
pituitêre klier vir GnRH kan direk met GnRHR vlakke gekorreleer word. Die muis GnRHR 
promotor bevat drie cis elemente met bindingssetels vir steroïedogeniese faktor 1 (SF1), 
naamlik setel 1 (-15/-7), setel 2 (-244/-236) en setel 3 (-304/-296) sowel as ’n aktiveerder 
proteïen 1 (AP-1) tipe konsensus sekwens (TGAGTCA) in posisie -336/-330. Terwyl setels 1 
en 2 en die AP-1 setel voorheen getoon is om by die regulering van transkripsie van die muis 
GnRHR (mGnRHR) promotor in party sellyne betrokke te wees, is die rol van setel 3 nog nie 
vantevore bestudeer nie. In hierdie studie is ondersoek of die transkripsie van die mGnRHR 
geen deur GnRH en glukokortikoïede in die LβT2 gonadotroop pituitêre sellyn gereguleer 
word, en die rol van setel 3 en die AP-1 setel en hulle binders, deur gebruik te maak van in 
vitro proteïen-DNA bindings studies en promotor-verslaggewer essais. Die rol wat setel 3 en 
die AP-1 setel in basale transkripsie van die mGnRHR gene in LβT2 selle gespeel het, was 
die eerste onderwerp wat in hierdie studie bestudeer is. Lusiferase verslaggewer plasmiede 
wat die eerste 600 bp van die mGnRHR promotor bevat het en waarin setel 3 en die AP-1 
setels óf wilde tipe óf gemuteer was, is gebruik. Two konstrukte is vanaf die wilde tipe 
konstruk berei, naamlik wilde tipe (LG), ’n setel 3 mutant (m3) en ’n AP-1 mutant (mAP-1). 
Transfeksie van LG, m3 en mAP-1 plasmiede in LβT2 selle is deurgevoer om te bepaal wat 
die effek van hierdie mutasies op die basale ekspressie van die mGnRHR gene was. Mutasie 
van setel 3 het ’n 1.5-voudige toename in die transkripsionele aktiwiteit van die mGnRHR 
promotor tot gevolg gehad. Dit suggereer dat setel 3 ’n rol in die inhibisie van die basale 
transkripsievlakke van die mGnRHR promotor in LβT2 selle speel. Mutasie van die AP-1 setel 
het tot ‘n 50% verlaging in basale transkripsievlakke van die mGnRHR promotor in LβT2 selle 
gelei. Dit suggereer dat die AP-1 setel betrokke is in die positiewe bemiddeling van die basale 
transkriptionele respons van die GnRHR promotor in LβT2 selle. Eksperimente wat gemik 
was om die meganisme van die cis-elemente (setel 3 en die AP-1 setel) op die mGnRHR 
promotor te verklaar, asook om die rol van proteïen kinase A (PKA) paaie, proteïene daarby 
betrokke en die effek van varieende dosisse vir verskillende tye van GnRH, sowel as die 
oorekspressie van PKA en die SF-1 proteïen, is deurgevoer. Dit is gevind dat setel 3 en die 
AP-1 setel nie betrokke by die GnRH respons is nie. Die resultate suggereer dat setel 3 
gedeeltelik betrokke is by die PKA respons van LβT2 selle. Setel 3 kan SF-1 proteïen bind 
soos getoon deur kompeterence elektroforetiese mobiliteits verskuiwings essais (EMSA). As 
EMSA’s deurgevoer is op die AP-1 setel is bevind dat die c-Fos proteïen nie betrokke is in die 
aktivering van die AP-1 setel nie. ’n Faktor is gevind om aan die AP-1 setel te bind wat nie ’n 
intakte AP-1 setel vereis het nie, wat gesuggereer het dat dit die c-Jun proteïen kan wees wat 
aan die AP-1 setel onder basale omstandighede bind.  
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’n Ander area wat ondersoek is, is of die GnRHR promotor gereguleer kan word deur 
deksametasoon (dex) óf via die AP-1 setel óf via setel 3. ’n Dosis en tyds-afhanklike toename 
in promotor aktiwiteit is waargeneem met dex. ’n Vereiste vir hierdie effek blyk om die 
teenwoordigheid van setel 3 en die AP-1 setel te wees, soos aangetoon deur die totale verlies 
aan response as hierdie twee setels individueel gemuteer is, en wat weereens in 
ooreenstemming met die funksionele interaksie tussen setel 3 en die AP-1 setel in LβT2 selle 
is. 
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 Chapter 1: Introduction 
1.1. Gonadotropin-Releasing Hormone and its Receptor: In the Hypothalamic-
Pituitary-Gonadal axis                         
1.1.1 Characterization of the GnRH-Receptor. 
 
The GnRHR protein has seven putative membrane-spanning domains and encodes a 327- to 328-
amino acid protein. The lack of a cytoplasmic carboxyl terminal tail makes the GnRHR a unique protein 
among the G protein-coupled receptors. 
  
The GnRHR promoter contains special features such as 1) the aspartic acid (D), arginine (R) and 
tyrosine (Y) (DRY) to aspartic acid (D), arginine (R) and serine (S) (DRS) consensus sequence, which 
is present on the second intra-cytoplasmic loop, 2) On the second and seventh intra-membrane 
domains there is an interchange of the conserved D and N residues and 3) it lacks the typical 
intracellular carboxyl terminus making it one of the smallest receptors that contain the seven 
transmembrane structure 1, 2.  
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The functional elements in the GnRHR I promoter regions of the mouse and rat genes.  The 
following boxes on the diagram above are represented as follows:  the shaded boxes and striped boxes 
are the TATA and CCAAT elements respectively. Black boxes represent elements, which have been 
functionally characterized. Putative elements shown as white boxes have been identified through  
 
ATG 
Rat 
SF-1 SF-1 CRE 
                           -314/-308       -295/-290       -245/-237        -180/-172      -126  -110/ -103                 -30          -15/-7       +1  
CRE 
SF-1 
   -1204/-1196    -983/-962     -871/-862      -697/--688    -657/-651          -461       -412/-395      -368          -352/-346    
SF-1 Pit-1 
PEA-3 SF-1 
AP-1 GRAS GATA LIM 
 
Mouse 
ATG SF-1 CRE AP-1 (SURG-2)GRAS 
          -391/-380              -354/-347              -336/-330           -244/-236  -200   -110/-103    –90       -62       -15/-7         +1   
SF-1 Oct-1, 
NF-Y
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Figure 1 legend continuation: 
promoter sequence analysis. The arrows indicate the transcriptional start sites, and the translational 
start site is represented as "ATG". Abbreviations: SF-1 = Steroidogenic Factor-1 binding site; Pit-1 = 
Pit-1 transcription factor binding site; CRE = cAMP response element; AP-1 = activator protein 1 
binding site; PEA-3 = phorbol ester response element; Oct-1 = octamer transcription factor-1 binding 
site; LIM = LIM-homeodomain factor binding site; GRAS = GnRH receptor activating sequence; SURG 
= sequence underlying responsiveness to GnRH, NF-Y = nuclear factor-Y binding site. Taken from 
Hapgood et al. (2005) 3. 
 
GnRHR genes that have been cloned and characterized include those from human, rat, mouse and pig 
2, 4 and many others. The genes in these species exist as single copies and have a high degree of 
sequence homology in their coding regions. 
 
The GnRHR gene contains three exons that are separated by two introns and is located on 
chromosome 5 in the mouse, chromosome 4q13.2-21.1 in humans and on chromosome 6 in sheep. 
The size of the introns as well as the sequence and length of the 5‘ and 3‘ untranslated regions differ 
dramatically between the different species even though the exon-intron boundaries are conserved 
between the species 2. Alternative splicing of the RNA transcripts can occur in the mouse and it results 
in multiple GnRHR mRNAs that code for truncated proteins. In the human and rat multiple GnRHR RNA 
transcripts have been discovered in tissues other than the anterior pituitary such as the ovaries, testes, 
brain, prostrate, breast and placenta 2. 
1.1.2 Characterization of the Gonadotropin Releasing Hormone (GnRH) 
The integration and precise orchestration of hormonal regulation at the hypothalamic, pituitary, and 
gonadal levels is necessary for the regulation of normal mammalian sexual maturation and reproductive 
function 1 and pregnancy in adults 5, 6, 7.  GnRH is the key endocrine hormone, which regulates 
reproduction.  
 
GnRH is a decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2)8, (see figure 2) which is 
released in synchronized pulses into the hypophyseal portal vascular system every 30-120 minutes 8. 
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Figure 2: A schematic representation of the mammalian GnRH. GnRH is in its folded conformation in 
which it is bound to the GnRH pituitary receptor. This figure was taken from Millar et al. (2004) 8. 
 
GnRH is delivered to the anterior pituitary where it binds specifically with high affinity to the G-protein 
coupled receptor (GPCR) on the pituitary gonadotropes called the GnRH receptor (GnRHR) 9. Of all the 
cells in the anterior pituitary gland, the gonadotropes only make up 8-15 %10. GnRH responsiveness 
depends on the number of GnRHR’s on the cell surface 11.  There is evidence to suggest that the 
GnRHR numbers are partially dependent upon the level of GnRHR mRNA in gonadotropes 11.  The 
partial correlation of GnRHR numbers with the changes in steady state GnRHR mRNA levels has been 
shown to be partly regulated at the transcriptional level 11.   
 
When GnRH was first isolated from the hypothalamus of mammals it was thought to be a unique 
peptide with its sole function being to regulate luteinizing hormone (LH) and follicular stimulating 
hormone (FSH) release from the pituitary, within the hypothalamus-pituitary-gonadal (HPG) axis 
(mentioned later). It later became apparent that diverse forms exist in vertebrates 8, which has 
subsequently led to the identification of 23 different forms of GnRH (see figure 3). For many years 
GnRH and its analogs have been used in the treatment of hormone-dependent diseases, as well as for 
assisted reproductive techniques 8.  There is also potential to use GnRH and its analogs as a male and 
female contraceptive 8. The stimulation of endogenous GnRHR levels by low doses of synthetic GnRH 
(in a pulsatile fashion) has also been shown to restore fertility in hypogonadal men and women 8. It has 
also been said to be an effective treatment for un-descended testes and delayed puberty 8. 
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1 2 3 4 5 6 7 8 9 10
Mammal pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly NH2
Guinea pig pGlu Tyr Trp Ser Tyr Gly Val Arg Pro Gly NH2
Chicken 1 pGlu His Trp Ser Tyr Gly Leu Gln Pro Gly NH2
Rana d. pGlu His Trp Ser Tyr Gly Leu Trp Pro Gly NH2
Seebream pGlu His Trp Ser Tyr Gly Leu Ser Pro Gly NH2
Salmon pGlu His Trp Ser Tyr Gly Trp Leu Pro Gly NH2
Medaka pGlu His Trp Ser Phe Gly Leu Ser Pro Gly NH2
Catfish pGlu His Trp Ser His Gly Leu Asn Pro Gly NH2
Herring pGlu His Trp Ser His Gly Leu Ser Pro Gly NH2
Dogfish pGlu His Trp Ser His Gly Trp Leu Pro Gly NH2
Chicken II pGlu His Trp Ser His Gly Trp Tyr Pro Gly NH2
Lamprey III pGlu His Trp Ser His Asp Trp Lys Pro Gly NH2
Lamprey I pGlu His Tyr Ser Leu Glu Trp Lys Pro Gly NH2
Chelyosoma I pGlu His Trp Ser Asp Tyr Phe Lys Pro Gly NH2
Chelyosoma III pGlu His Trp Ser Leu Cys His Ala Pro Gly NH2
Ciona I pGlu His Trp Ser Tyr Ala Leu Ser Pro Gly NH2
Ciona II pGlu His Trp Ser Leu Ala Leu Ser Pro Gly NH2
Ciona III pGlu His Trp Ser Asn Gln Leu Thr Pro Gly NH2
Ciona IV pGlu His Trp Ser Tyr Glu Phe Met Pro Gly NH2
Ciona V pGlu His Trp Ser Tyr Glu Tyr Met Pro Gly NH2
Ciona VI pGlu His Trp Ser Lys Gly Tyr Ser Pro Gly NH2
Ciona VII pGlu His Trp Ser Asn Lys Leu Ala Pro Gly NH2
Octapus pGlu His Trp His Phe Ser Trp His Pro Gly NH2
 
 
 
Figure 3: Primary amino acid sequence of structural GnRH variants spanning approximately 600 million 
year of evolution. Areas within the left and right box are the conserved NH2 and COOH-terminal 
residues that play important functional roles. Figure taken from Millar et al. (2004) 8. 
 
Expression of the gonadotropin subunit genes LH and FSH as well as their synthesis and release is 
regulated by the binding of GnRH to the GnRHR 9 (see figure 4). When a pulse of GnRH is delivered to 
the anterior pituitary a pulse of LH is released, as LH tends to be stored and is largely dependent on 
GnRH for secretion. A FSH pulse is also released although it is less distinct as FSH is constitutively 
secreted and more dependent on biosynthesis for its secretion 8. Ovulation, corpus luteum formation (in 
females) and androgen secretion (in males) is regulated by LH 1, whereas growth and maturation of the 
ovarian follicles (in females) and spermatogenesis (in males) is regulated by FSH 1. 
 
Asn Gly 
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Figure 4: The Hypothalamus-Pituitary-Gonadal (HPG) axis. GnRH is released from the hypothalamus 
to the anterior pituitary where it binds to GnRHR and releases LH and FSH. It then stimulates the 
production of testosterone in males and oestrogen and progesterone in females. The HPG axis has a 
negative feedback cycle.  When testosterone, FSH and LH increases to over the threshold the 
production of GnRH in the hypothalamus is stopped. Positive signs indicate the positive loop system 
and negative signs indicate the negative loop system. Diagram by Fernandes (2006). 
 
A change in GnRH pulse frequencies causes an asynchronous pattern of LH and FSH release, which 
results in the modulating effects and the differences in the half-lives of these two hormones 8. The 
frequency and amplitude of GnRH regulates the GnRHR 12. 
 
 
 
 
 
GnRH 
LH and 
FSH 
LH and 
FSH 
Hypothalamus 
Anterior Pituitary 
Ovaries: Release 
of Oestrogen and 
Progesterone 
Testis: Release 
of testosterone 
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1.1.3 GnRHR promoter 
The first proximal promoter that was isolated and characterized was the mouse GnRHR promoter 12.  
1.2kb of 5’ flanking region of the mouse GnRHR gene (designated -1164/+62 relative to the major 
transcriptional start site) has been shown to contain tissue-specific promoter activity 2.  At 62 
nucleotides upstream of the translational start site a major transcriptional start site was identified, which 
appears not to use a TATA box (in αT3-1 cells) 1 although there may be other elements that are 
important for the accurate start site for transcription such as the GATA motif at position -30 2.  
 
On the mouse GnRHR promoter (in αT3-1 cells) gonadotrope-specific activity has been reported to be 
mediated via a tripartite basal enhancer consisting of  a steroidogenic factor-1 (SF-1) binding site at –
244/-236 13 a consensus activator protein-1 (AP-1) site at –336/-380 and a GnRHR-activating sequence 
(GRAS) at –391/-380 14 (see figure 1).  
 
The transcriptional start site in αT3-1 cells of the rat proximal GnRHR I promoter was first reported to be 
at 103bp upstream from the start codon containing a putative TATA box 23bp upstream from the 
transcriptional start site 15.  Later the group of Pincas et al.(1998) 16 discovered that there was multiple 
transcriptional start sites in αT3-1 cells consisting of four clustered around –103 and one situated at –30 
together with several minor start sites 16 (See figure 1).  The rat GnRHR promoter cooperates with a 
distal enhancer element called GnRHR-specific enhancer (GnSE), which lies between –1135 and –753 
and facilitates gonadotrope-specific expression 16.  For full functionality, the distal enhancer can only 
function in the context of the proximal promoter and requires the SF-1 site at –245. Therefore, in the 
mouse and rat GnRHR promoters one can clearly see that the mechanisms involved in gonadotrope-
specific expression are different between the mouse and rat GnRHR promoters. 
1.2 Regulation of the GnRHR 
Several different kinase proteins which target various transcription factors are important in the 
regulation of the GnRHR promoter.  These key “players” include protein kinase A (PKA), protein kinase 
C (PKC), Steroidogenic factor-1 (SF-1) and the activator protein-1 (AP-1). 
1.2.1 Protein Kinase A (PKA) and Protein Kinase C (PKC) in the signal 
transduction pathway of the GnRHR gene. 
The regulation of the GnRHR gene by GnRH occurs via two major signalling transduction pathways 
namely PKA or PKC. There are many suggestions that different cell lines lead to the use of different 
signalling pathways. For instance, Maya-Nunez et al. (1999) 17 found in GGH3 cells that the major 
signalling pathway involved in GnRH-dependent GnRH receptor gene regulation in the rat was the PKA 
pathway. Norwitz et al. (1999) 2 found that in αT3-1 cells the major signalling pathway that causes a 
response to GnRH in the mouse and the human GnRH receptor gene is through the PKC pathway and 
not via the PKA pathway, which was in contrast to what Maya Nunez et al. (1999) 17 found in GGH3 
cells. White et al. (1999) 18 found that the activation of the GnRHR promoter by GnRH in αT3-1 cells 
was dependent on the AP-1 binding site and was found to mediate via the PKC pathway. Even if the 
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response of the GnRHR promoter to GnRH in αT3-1 cells is regulated via the PKC pathway, it is 
possible that the PKA pathway can also regulate the gene in response to other signalling molecules 
that activate the PKA pathway. 
1.2.2 Characterization of Steroidogenic Factor-1 (SF-1). 
SF-1 protein is an important regulator of the mGnRHR promoter and more background will be given on 
the SF-1 transcription factor since it has been shown to be involved in mGnRHR transcriptional 
regulation. SF-1 was discovered in the early 1990s and was found to be a key regulator of 
steroidogenic genes involved in steroidogenesis 19. The 53kDa protein was also called Ad4BP (Adrenal 
4 Binding-Protein), because it was identified as the protein that bound to the Ad4 cis-element of the 
bovine cytochrome P-450 gene (CYP11B) 20, and formally known as NR5A1 (nuclear receptor 
subfamily 5, group A, member 1) 21. The SF-1 protein is expressed in steroidogenic tissues and has 
also been identified in other tissues 21. The cDNA of SF-1 was successfully cloned by two teams 
Morohashi et al. (1992) 22 and Honda et al. (1993) 20. Both of these teams identified a 53kDa protein 
and a 1383bp cDNA that encoded for a protein of 461 amino acids 20, 22. Through sequence homology 
researchers found that mouse SF-1 and Drosophila Ftz-F1 had a high degree of homology to each 
other. The gene encoding SF-1 was called Ftz-f1 in Drosophila.  Ftz-F1 transcription factor controls 
fushi tarazu homeotic gene expression 19. Four different proteins are encoded for by this gene namely 
ELP1, ELP2, ELP3 and SF-1, which is produced by using alternative promoters and splicing. There has 
been some suggestion that embryonal long terminal repeat-binding protein (ELP) in Drosophila plays a 
role in regulating transcription of nuclear receptors. SF-1 on the other hand has been shown to be the 
key activator of steroidogenic endocrine function in mammals 19. 
 
SF-1 is a member of the orphan nuclear receptor superfamily, which includes receptors for steroid, 
thyroid, and retinoid hormones 21. The reason SF-1 is called an orphan nuclear receptor is because it 
does not have a bona fide SF-1 ligand. These orphan receptors have conserved functional domains 
that include two zinc fingers, which mediate its binding to DNA, a proline rich domain, which has been 
proposed to mediate transcriptional activation, and a AF-2 transactivation domain 19. 
 
The first zinc finger of SF-1 contains a proximal (P) box and the second zinc finger contains a distal (D) 
box and between these two zinc fingers is an intervening linker region that seems to be conserved 
among human, bovine, rat and mouse 23 (see figure 5). The P box for the DNA sequence half sites of 
the hormone responsive elements determines the recognition, whereas the D box determines the 
appropriate spacing of these half sites. Adjacent to the D box is another element, which recognizes 
additional bases termed the A-box.  
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Figure 5: Regulation of transcription by SF-1.  The P-Box is shown in green whereas the A-Box is 
shown in yellow.  Taken from Achermann et al., (2002) 24. 
 
SF-1 was found to be expressed in the embryonic forebrain, hypothalamus and the pituitary.  
Researchers found that in SF-1 knockout mice the expected birth rate frequency was 25% indicating 
that SF-1 was not required for embryonic survival 25.  However these researchers did find that mice that 
had the SF-1 knockout had external female genitalia, irrespective of genetic sex and also had failure to 
produce testicular androgens and that their survival rate after birth was poor, which was due to a 
corticosteroid deficiency, indicating the important role that SF-1 plays in androgen and corticosteroid 
biosynthesis 25.  In these SF-1 knockout mice adrenal glands and gonads were completely absent 
revealing the importance of SF-1 in the development of these tissues 25.  Another study with SF-1 
knockout mice showed a lack of the ventromedial hypothalamic nucleus, which is generally rich in 
steroid hormone receptors and has been shown to be involved in female reproductive behaviour 25.  The 
spleen of mice that contained the SF-1 knockout gene showed severe developmental defects. 
Therefore, from these different studies it is clear that SF-1 is a key regulator at multiple levels of the 
hypothalamus-pituitary- adrenal (HPA)/HPG axis (explained in more detail later).  
1.2.3 Binding of SF-1 to DNA 
It is well established that most nuclear receptors bind to DNA in one of two ways either by direct or 
inverted dimerization. However, SF-1 binds as a monomer to DNA. SF-1 DNA-binding sites have been 
identified and shown to be functional in several promoters of genes involved in steroidogenesis.  The 
activation of transcription is caused by the SF-1 protein binding to the SF-1 site on the promoter 
resulting in the shuttling of nuclear receptors from the cytoplasm, where they bind to their cognate 
ligands, to the nucleus. Nuclear localization signals (NLS) are important for the shuttling of nuclear 
receptors. SF-1 contains one NLS downstream of the DNA binding domain (DBD) (amino acids 89-
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101), and is important for transcriptional activity 19. In the ligand-binding domain (LBD) of SF-1, helices 
1 and 12 are able to adopt an active confirmation independently of a ligand. This occurs due to the 
phosphorylation of a serine residue at position 203. SF-1 also contains a conserved AF-2 domain, 
which is responsible for recruiting co-activators. The AF-2 domain of SF-1 co-operates with two 
activating domains, which are present downstream from the DBD. The two domains are the proximal 
activation domain and helix H1. The proximal activation domain overlaps with the hinge area and helix 
H1 is present in the putative LBD (amino acid 187-245). These domains are important for maximal SF-1 
activity together with the co-activator SRC-1 26.  
 
SF-1 is said to be a master protein directing its effects at multiple levels of the reproductive axis, as it is 
present at multiple levels of the HPG axis 26. The SF-1 site present at position -250 to -232 is part of the 
tripartite enhancer, which confers gonadotrope-specific expression in murine GnRHR gene. The 
mutation of this site resulted in a 58% decrease in promoter activity 14. On the human GnRHR promoter 
the SF-1 site is situated at -140/-134 and has been shown to be involved in mediating high cell-specific 
expression in αT3-1 cells 27. This high cell-specific expression however has not been assigned for 
similar sites in the mouse and rat GnRHR promoters (position -15/-7). 
1.2.4 Regulation of SF-1 expression 
SF-1 is involved in mediating the PKA response in certain genes.  What this means is that the SF-1 
protein is required for the PKA pathway-dependent increase in transcription in certain genes.   
 
There are two mechanisms thought to be involved in regulating SF-1, which are  
1) SF-1 transcriptional activity can be affected by it being a direct target for PKA-dependent 
phosphorylation resulting in the SF-1 protein binding to the target promoter or,  
2) The levels of the SF-1 protein can be affected by PKA, via a PKA dependent regulation of 
the SF-1 protein, where the target for PKA is the transcription factor that regulates the 
expression of the SF-1 gene (i.e. indirect mechanism).   
 
The indirect effect was investigated by Shapiro et al. (1996) 28 and found that when rat granulosa cells 
were incubated with 8-Br-cAMP there was a 2-fold increase in SF-1 mRNA.  Therefore, they suggested 
that this increase in SF-1 mRNA could contribute to the increase in transcription of the GnRHR gene.  
Since the increase in SF-1 mRNA appeared to be insufficient to explain the full increase in GnRHR 
activity, the authors suggested that SF-1 protein could also be modified post-translationally to increase 
its activity in response to the stimulation of the PKA pathway 28.  Zhang et al. (1996) 29 showed that 
when they performed transfection studies on mouse Leydig MA-10 and adrenocortical Y-1 cells that the 
SF-1 protein can bind to an element in the promoter of the cytochrome P450 17α-Hydroxylase/c17-20 
lyase gene and that SF-1 mediates the stimulatory effect of the PKA pathway on transcriptional activity 
29. 
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There are other binding sites on the rat aromatase gene promoter that are required for transcriptional 
activation by PKA e.g. cAMP response element (CRE)30.  The binding sites required for transcriptional 
activation via PKA are different for different promoters. For instance in the human aromatase gene 
promoter there appears to be no classical CRE elements present and it is thought that the PKA-
stimulated transcription is due to increased levels and DNA-binding of SF-1 31.  In conclusion the exact 
mechanism whereby SF-1 mediates the PKA response differs from gene to gene as well between the 
same gene in different species. 
1.3 Different model systems 
There are several model systems, which are currently being used in order to study the regulation of the 
mouse GnRHR gene. The most commonly used model systems are transformed cell lines, which 
originated from specific tissue types. Cell lines tend to be mostly derived from tumors, which are 
induced in transgenic mice. Below are some common cell lines used to study the regulation of the 
mouse GnRHR gene in the pituitary: 
1.3.1 GGH3 cells. 
GGH3 cells are rat GH3 cells, which are somatolactotropic in origin, and stably express the rat GnRHR.  
This cell line was engineered by cotransfecting rat GH3 cells with the rat GnRHR expression vector 
(pcDNA1-GnRHR) and a pSVneo plasmid expressing the neomycin resistance gene1. The GGH3 cell 
line is indistinguishable from its parental cell line GH31. On the GGH3 cells there are specific, high-
affinity binding sites for GnRH and GnRH analogs, although this is not present in the parental GH3 cell 
line. Activation of these cells by GnRH results in the release of prolactin and growth hormone. It has 
been found that GnRHR in GGH3 cells can couple to both Gαq and Gαs, therefore either activating 
adenylyl cyclase resulting in the activation of PKA or activation of phospholipase C followed by PKC, 
which can result in the activation of GnRHR gene transcription 32, 33. 
 
The advantage of this cell line is that the GnRHR’s expressed in these cells couple to the same G-
proteins as the endogenous GnRHR’s in primary rat gonadotropes resulting in the assumption that the 
same signalling pathways will mediate GnRH action in both cell types 34.  
1.3.2 αT3-1 cells 
The αT3-1 mouse clonal cell line represents precursor pituitary gonadotrope cells.  αT3-1 cells came 
about when a fusion gene containing a 1.8kb of the 5‘- flanking sequences of the human glycoprotein 
hormone α-subunit was linked to the simian virus-40 (SV-40) T-antigen oncogene and was used to 
produce transgenic mice 35. This resulted in tumors in the anterior pituitary and gave rise to the αT3-1 
cell line. The αT3-1 cells have provided a useful cell model for the study of GnRHR and GnRH action 35. 
The advantage of these cells is that they have retained several differential functions of gonadotropes, 
such as gonadotropin α-subunit expression, synthesis and secretion, as well as expression of the 
GnRHR and receptor-dependent responsiveness to GnRH 35. These cells express the estrogen, 
progesterone, androgen and glucocorticoid receptors as well as the SF-1 mRNA and protein 36. 
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The disadvantage of these cells is that they do not express the FSH and LH β-subunit genes indicating 
that these cells are derived from precursor cells that were not fully differentiated into gonadotropes 35.  
In αT3-1 cells the GnRHR appears to couple to the Gαs subunit therefore resulting in the activation of 
PKA and ultimately in the activation of GnRHR gene transcription 33.  
1.3.3 LβT2 cells 
The immortalized gonadotrope cell line (LβT2) was derived from tumors generated in transgenic mice, 
by a similar method to the preparation of αT3-1 cells 33, 37. LβT2 cells are more differentiated than the 
αT3-1 cell line. These cells were generated later in ontogeny as compared to the αT3-1 cell line and 
thus represent a more mature gonadotrope precursor. In LβT2 cells the GnRHR can couple to the Gαq 
and the Gαs subunits. Whether the PKA and PKC pathways are involved in transcriptional regulation of 
the GnRHR gene in response to GnRH in these cells are not known (Sadie personal communication).  
 
The advantage of LβT2 cells is that they exhibit more differentiated gonadotrope-like characteristics, 
such as the expression of both the α and β-subunit of LH and the mRNA for the GnRH receptor is 
expressed in this cell line. They also express the oestrogen receptors, and oestrogen inducible 
progesterone receptor 33. The disadvantage of these cells is that they do not express the FSH β-
subunit. 
1.4 Basal regulation of GnRHR gene expression 
Duval et al., (1997) 14 identified a tripartite enhancer that appears to be responsible for regulating the 
basal levels of the mouse GnRHR gene in αT3-1 cells 14. The tripartite enhancer included binding sites 
for steroidogenic factor-1 (SF-1), activator protein-1 (AP-1) and contains a GnRHR activating sequence 
(GRAS).  
 
Experiments were carried out on each of the cis- elements mentioned above to understand what the 
role of each cis-element was in basal regulation. It was found that the cis-elements AP-1, SF-1 and 
GRAS appeared to contribute equally in the basal regulation of mGnRHR promoter 14 leading to a 60% 
decrease in promoter activity if any one of these sites was mutated. When combinations of any 2 cis-
elements were mutated it resulted in an 80 % decrease in promoter activity. If all three sites were 
mutated a complete loss of basal promoter activity was seen, with the construct showing activity similar 
to that of a promoterless vector 14. 
 
It has been reported that the basal regulation of the rat and sheep GnRHR genes appears to be 
mediated primarily through the protein kinase A second messenger pathway14. Researchers have also 
found that on the rat promoter the AP-1 site is involved in the basal promoter activity of the GnRHR 
gene 14. 
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In some pituitary cell lines such as LβT2 and GGH3 cell lines the mouse CRE has been shown to be 
essential for basal promoter activity although the rat CRE does not seem to be involved in basal 
promoter activity in αT3-1 cells 38. 
1.5 Homologous regulation of GnRHR gene transcription 
Homologous regulation of GnRHR gene expression is an established mechanism for controlling the 
sensitivity of gonadotropes to GnRH. When a low dose of GnRH is administrated in a pulsatile fashion 
an increase in expression levels of the mGnRHR promoter is observed 12. Conversely, continuous 
administration of GnRH at a high concentration results in a down-regulation of the GnRHR 12 via post-
translational mechanisms although transcriptional mechanisms can also contribute 39, 40, as was found 
in αT3-1 cells.  Two sites have been identified that contribute to the increase observed in GnRHR 
promoter transcription with continuous stimulation (4-6 hours) with 100 nM GnRH in αT3-1 cells. These 
sites are sequence-underlying responsiveness to GnRH-1 (SURG-1) containing binding sites for 
nuclear factor-Y (NF-Y) and Oct-1 41 and sequence underlying responsiveness to GnRH-2 (SURG-2) 
containing the AP-1 binding site. 
 
In αT3-1 cells the protein kinase C (PKC) pathway is involved in the GnRH response and leads to the 
activation of the c-Jun N-terminal kinase (JNK) pathways resulting in an increase in the expression of 
the AP-1 family members and the binding of these proteins to the SURG-2 site 42, 18.  SURG-1 and 
SURG-2 can respond independently to GnRH and the AP-1 site is important for conferring GnRH 
responsiveness 13, which was shown in transgenic mice 42. 
 
In LβT2 cells an increase in the endogenous protein and mRNA levels of the mGnRHR, was revealed 
when these cells were exposed to long term pulsatile GnRH stimulation 43. Other researchers found that 
the activity of a transfected mouse GnRHR promoter-reporter construct containing 1.2kb of GnRHR 
promoter in LβT2 cells showed only minimal increases when stimulated either with continuous GnRH or 
in a pulsatile fashion with GnRH 9. 
 
The number of GnRHR’s does appear to correlate with GnRH responsiveness 44. In rat pituitary cultures 
stimulated with GnRH in a pulsatile fashion an increase in GnRHR mRNA levels was observed 45. 
Suggestions have been that this mechanism involves mitogen activated protein kinase (MAPK) and 
maybe the cyclic 3’, 5’-adenosine monophosphate (cAMP)/protein kinase A (PKA) pathways 46, 47. 
 
Depending on the cell line different G-protein coupled receptors (Gq/11α and Gs) can be activated 
through signals that occur when GnRH binds to the GnRHR. The G-proteins are described as 
heterotrimeric signalling molecules, which are composed of three subunits: α, β and γ.  These subunits 
dissociate upon the exchange of GDP for GTP, which is induced by the receptor resulting in a free Gα 
as well as a dimer of Gβγ subunits. In the past few years many isoforms of the different subunits have 
been cloned and classified according to the subtype of their α subunit 48. There are four different 
subtype groups, mainly Gs, Gi, Gq and G11. 
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The coupling of different signal transduction systems to a 7 transmembrane segment receptor (TMS) is 
dependant on several factors, which include receptor/G-protein affinity and the density of the receptors 
48. Many factors may change the accessibility of G-proteins to receptors such as the type of cells, the 
concentration of the G-proteins, the density of the receptors and the compartmentalization of the signal 
transduction machinery 48. 
 
Diverse downstream signalling pathways are initiated by all of the Gα subunits, as well as the 
dissociated βγ subunits and other receptor-interacting proteins 33, 34. When Gαs dissociates from its βγ 
subunits, it exerts its action through the interaction and stimulation of adenylyl cyclase activity, which 
results in an increase in cAMP.  The initial phase of GnRH action in certain cell lines such as GGH3 
cells and LβT2 cells involves the stimulation of phospholipase C (PLC), which is caused by the coupling 
of the GnRHR Gq|11 34. PLC leads to the production of the second messenger inositol (1, 4, 5)-
triphosphate (IP3), which induces Ca2+ mobilization, and diacylglycerol (DAG). DAG and Ca2+ together 
can lead to the activation of PKC or MAPK 33, 34. The binding of GnRH to the GnRHR in GGH3 causes 
an influx of calcium suggesting that calcium dependant signal transduction pathways participate in the 
activation of the GnRHR promoter activity when GnRH is present 34. 
 
These signals from the G-protein coupled receptors converge with the MAPK gene family, which 
regulates cell growth, division and differentiation through the transduction of externally derived signals 
49. MAPK translocates into the nucleus and is activated by phosphorylation. The phosphorylated MAPK 
in turn activates nuclear transcription factors, which are involved in DNA synthesis and cell division 36. 
MAPK is involved in the regulation of the GnRHR gene and it has been shown that MAPK can be 
activated through GnRH in pituitary organ culture 49. The Gαq coupled receptors stimulate MAPK in a 
PKC-dependent manner 50. Reiss et al. (1997) 49 investigated the mechanism of activation of MAPK 
(ERK1 and ERK2) by GnRH in αT3-1 cells and found that the ERK1 isoform was mainly stimulated 
through the signalling of the GnRHR and it also involved the Ca2+ dependent pathway 49. Experiments 
performed in cultures of primary rat pituitary cells showed that the activation of PKC increased the 
levels of the gonadotropin subunit messenger RNAs. Alternatively when PKC was depleted through 
phorbol ester treatment it resulted in a decrease in the stimulation of the LHβ-gene expression by 
GnRH 49. 
1.6 Stress and reproduction 
1.6.1 Glucocorticoids (GC) 
GC are steroid hormones that are synthesized and secreted from the adrenal cortex in response to 
stress via the HPA axis. An example of GC is cortisol in mammals. GC are extremely important for the 
protection of the body against stress by regulating glucose metabolism and blood pressure 50. An 
important role of GC is the dynamic modulation of the inflammatory and immune responses. The way 
this occurs is via cross talk with transcription factors and signalling pathways. 
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During the time of inflammation the lymphocytes/macrophages are activated leading to the production 
of inflammatory cytokines, namely tumor necrosis factor α (TNF-α) and interleukin-1β (IL-1β). In turn 
these cytokines activate components of the inflammatory system as well as the expression and release 
of corticotrophin-releasing hormone (CRH). The increase in CRH leads to the production of 
adrenocorticotropic releasing hormone (ACTH), stimulating the adrenal cortex, which results in the 
production and secretion of GC 51. GC are anti-inflammatory hormones and have effects on many cell 
types including T cells, macrophages, eosinophils, neutrophils, mast cells, endothelial and epithelial 
cells thus creating a classical endocrine feedback loop. 
 
The action of GC is caused by the interruption of pro-inflammatory, cytokine-mediated signalling 
pathways and by causing apoptosis in certain cells of the immune system. In several immune and 
inflammatory diseases, which include rheumatoid arthritis, inflammatory bowel disease and asthma, 
exogenous synthetic GC are prescribed. The biological actions of GC as anti-inflammatory agents exert 
their actions via the interaction of this hormone with its cognate receptor, which is a member of the 
nuclear receptor superfamily of proteins 51. 
 
The regulatory role of GC occurs in many biological processes and has a great influence on many 
physiological functions. Using GC as anti-inflammatory and immunosuppressive drugs results in severe 
side effects such as osteoporosis, diabetes and psychotic manifestations.  
1.6.2 The HPG-HPA link. 
It appears that an activated HPA axis leads to an inhibition in the HPG axis via suppression of the 
GnRH pulse generator (see figure 6).  HPA activation leads to the release of the neurohormone CRH. 
The release of CRH causes an increase in the ACTH and cortisol levels resulting in the activation of 
the sympathetic nervous system causing an increase in glucose levels, heart rate and blood pressure 
51. The locus cenileus/autonomic system releases norepinephrine from several central networks as a 
result of stress. Researchers have suggested that it could be possible that CRH is not the sole HPA 
neurohormone involved during the stress response as vasopressin of the paraventricular origin was 
found to be co-released with CRH during stress 51. Many studies are under way to link the HPA axis to 
the HPG axis. Recently, it was found that when rodents and non-human primates were administered 
with CRH it resulted in an immediate decrease in pulsatile GnRH and LH release although this has not 
been the case in humans. These studies are difficult to perform in humans at it is difficult to keep the 
stressful conditions constant, as humans are capable of adapting to their environment 51. 
 
In humans it is known that when the HPA axis is activated by stress or by psychological disturbances it 
results to an inhibition of the HPG axis (Figure 6). It has been found that if stress is severe enough that 
it can lead to suppression of the normal menstrual cycle, which is referred to as functional hypothalamic 
amenorrhea and can, lead to infertility when fully established 53. Researchers have found it difficult to 
identify the threshold of stress that could interfere with the normal cycle. Many researchers have 
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however agreed that the final neuroendocrine event responsible in the suppression of the normal cycle 
is a decrease in the GnRH pulse generator resulting in a decrease in the hypothalamic GnRH activity 52 
causing a decrease in GnRHR number, leading to a decrease in the LH pulse frequency and ultimately 
causing deficiencies in the normal menstrual cycle 52. GC are released during stress and have been 
implicated in the regulation of GnRH release in the hypothalamus 54.  High levels of cortisol have also 
been associated in the reduction of circulating LH 54.  The mechanism behind the regulation of GnRH 
by GC is a suppression of GnRH in the hypothalamic area 55, which ultimately leads to a decrease in 
the GnRH pulse-generating centre 56.  GCs also however act directly on the pituitary, diminishing the 
responsiveness of the gonadotrope cells to GnRH 57.  
 
Figure 6: The HPA-HPG link and the negative/positive feedback loops between the axes.  
Abbreviations are as follows CRH = Corticotrophin-releasing hormone, ACTH = Adrenocorticotropic 
hormone, LH = Luteinizing hormone, FSH = Follicule stimulating hormone.  Arrows indicate positive 
(+) or negative (-) feedback. Diagram by Fernandes (2006). 
 
Researchers have said that in times of stress the HPA axis increases and the HPG axis decrease 3.  
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at the expense of gonadal activity.  At the time of stress, stress related hormones can affect the HPG 
axis at 3 different levels: 1) hypothalamus, resulting in the inhibition of GnRH, 2) the pituitary, which 
interferes with the GnRH induced LH release, 3) and at the level of the gonads altering the stimulatory 
effect of the gonadotropins on sex steroid secretion 3. Therefore, stress can have both a stimulatory or 
inhibitory effect with regard to reproduction 58. 
 
 
1.6.3 Glucocorticoid Receptor (GR) 
The GR is a transcription factor which is capable of regulating several genes when its cognate hormone 
(GC) binds the receptor. This regulation of genes can occur either in a positive or negative way 50. The 
GR belongs to the steroid hormone receptor family and is structurally similar to the progesterone (PR), 
mineralocorticoid (MR), androgen (AR), and oestrogen (ER) receptors 59. 
 
The GR consists of a variable amino-terminal transactivation domain and a central and well-conserved 
DNA-binding domain (DBD), with a moderately conserved carboxy-terminal domain, which is 
responsible for ligand binding 60. The N-terminus contains an AF-1 activation domain. This domain is 
important for the enhancement of transcription as well as the association of the receptor with basal 
transcription factors 61. The DNA binding domain is highly conserved amongst nuclear receptors and it 
contains two zinc fingers, which are important for dimerization and binding of DNA. The C-terminus is 
where the hormone binds or when hormone is not present it is also the site where the heat shock 
proteins bind. There are other sites that are contained within the C-terminus such as the nuclear 
localization signals as well as the ligand dependent activation domain (AF-2) 61. 
 
The human GR contains two isoforms, namely GRα and GRβ, which are generated by alternative 
splicing of a single gene. The difference between the two isoforms is that GRα is a 94kDa protein which 
consists of 777 amino acids and binds to the hormone resulting sometimes in the activation of the 
glucocorticoid-responsive genes whereas the GRβ is a 91kDa protein which consists of 742 amino 
acids and cannot bind to the hormone or any glucocorticoids 62. Both isoforms have the first 727 amino 
acids in common meaning they can both transactivate and they both have the DNA-binding domains.  
The difference between the two isoforms is in the C-terminus.  GRβ has the last 50 amino acids 
residues different to GRα and has a unique additional 15 non-homologous amino acid sequence 62.  
This variation makes GRβ unable to bind GC resulting in no translocation into the nucleus. GRβ is 
however capable of binding to the glucocorticoid response element (GRE) and forms homodimers and 
heterodimers with GRα 62. 
1.6.4 Binding of glucocorticoids to the glucocorticoid receptor 
The GR is present in the cytoplasm bound to heat shock proteins (hsp90, hsp70, hsp56, hsp40) and 
low-molecular weight protein (p23) and many immunophilins. GCs have a lipophilic nature and therefore 
can easily diffuse passively through the plasma membrane and bind to the GR. Upon binding of GCs to 
GR, heat shock proteins are released and the GR becomes an activated transcription factor. When the 
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heat shock proteins are released the nuclear localization signals are exposed resulting in the rapid 
translocation of the ligand-bound receptor into the nucleus. In the nucleus, the ligand-bound receptor 
dimerizes with another ligand-bound receptor, which can then bind to the glucocorticoid-response 
element (GRE), which allows the receptor to interact directly or through coactivators to mediate positive 
or negative transcriptional responses of glucocorticoid-sensitive genes 51, 63 (see figure 7). 
 
 
 
 
                                                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: The mechanism of glucocorticoid binding to the glucocorticoid receptor resulting nuclear 
translocation leading to transactivation. Abbreviations: GR = glucocorticoid receptor; Hsp 90 = heat 
shock protein 90; GRE = glucocorticoid response element and ? = unknown proteins.  Diagram by 
Fernandes (2006). 
 
When GCs bind to the receptors they can modulate gene transcription in the nucleus in 2 ways. Firstly 
they can activate and secondly they can repress the transcription of target genes. Activation of 
transcription occurs when there is direct interaction between the GR and a GRE. However, repression 
of transcription can occur in two ways: 1) If there is an indirect action of GR mediated by a response 
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element for another transcription factor via GR-protein interaction, 2) if GR displaces another general or 
regulatory transcription factor 63. 
 
1.6.5 Direct activation/repression of transcription via the GR 
Once the GR is activated by GCs the activated GRs proceed rapidly to the cell nucleus and can bind as 
a homodimer to a GRE in the promoter region target genes (as mentioned above). This is the classical 
model for GR action which is characterized by the GR interacting with GREs (see figure 7). The GRE 
has been reported to have two defined stretches of nucleotides separated by undefined nucleotides 
creating two half sites.  The concensus sequence of GRE is:  5`AGAACAnnnnTGTTCT3` where n can be 
any nucleotide.  Therefore, the DNA binding domain of GR binds only to specifically spaced target half 
sites on the DNA and the specific DNA associations induce receptor dimerization.  When the GR 
homodimer binds to the GRE the homodimer interacts with the basic transcription machinery either 
directly or indirectly 64.   
 
1.6.5.1 nGRE mechanism 
In some promoters an activated GR can also bind directly to a so-called negative GRE (nGRE) resulting 
in inhibition of transcription.  It is thought that the GR binds to the nGRE and interferes with the 
transcriptional activation by other transactivating factors.  The GR can bind to nGREs as a monomer, 
which leads to a suppression of gene expression as found for the keratin and CRH genes.  Secondly, 
the GR can bind to the nGRE and antagonize the effect of a transcription factor that would naturally 
induce transcription.  This can occur because the GR-binding site overlaps with the binding site for a 
required transcription factor in the promoter, which is termed competitive DNA binding 64. 
 
1.6.5.2 Coactivators 
There are also transcriptional co-activators for the GR which result in an enhanced transcriptional 
activity of the ligand-bound GR.  Examples of these co-activators are the steroid receptor co-activator 
(SRC) family which consists of SRC-1, GRIP-1 and SRC-3 to name a few.  Other proteins which are 
also involved as GR co-activators are CREB binding protein (CPB) and STAT-5. The co-activators in 
turn enhance transcription by recruiting secondary co-activators containing histone acetyltransferase 
activity (e.g. CBP) as well as recruitment of protein methyltransferases.  These proteins are involved in 
remodelling of chromatin at the respective promoter region, thereby allowing other transcription factors 
to bind previously inaccessible DNA 64. 
1.6.6 Indirect inhibition of transcription via the GR 
Other mechanisms besides those involving nGREs can also result in GR-mediated repression, as 
occurs for genes which are positively regulated by pro-inflammatory transcription factors composed of 
dimers of Jun and Fos proteins belonging to the AP-1 family.  These genes include those for cytokines 
and chemokines such as Interleukin-1, TNF-α, IL-4, IL-5 and IL-8. This is a so-called tethering effect 
which involves no direct binding of the GR to the DNA, but rather the GR binds to another transcription 
factor and inhibits its function, usually via blocking the recruitment of the basal transcription machinery.  
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Examples of these transcriptions factors are CREB, orphan nuclear receptor Nur77 65 (also known as 
NGF1-B) and AP-1 66 (see figure 8). 
 
1.6.6.1 A new mechanism of transcription via the GR 
An interesting scenario occurs when both GRE and an AP-1 binding site overlap to form one element 
with new properties which can bind both the GR as well as AP-1 proteins simultaneously.  Depending 
on the nature of the AP-1 proteins bound, the outcome for transcriptional regulation differs. Repression 
is observed in the presence of the liganded-GR if only c-fos but no c-jun are present, stimulation of 
transcription occurs in the presence of only c-jun (c-jun homodimer), and if both c-jun and c-fos are 
present (c-jun/c-fos heterodimer) then repression occurs 67.  The liganded-GR remains bound to the 
GRE in these scenarios.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: The tethering mechanism of glucocorticoids binding to the glucocorticoid receptor resulting 
in nuclear translocation leading to transrepression. Abbreviations: GR = glucocorticoid receptor; Hsp90 
= heat shock protein 90 and AP-1 = activator protein-1. Diagram by Fernandes (2006). 
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1.6.7 Characterization of the AP-1 site and the proteins involved 
AP-1 is a family of transcription factors, which can form homodimers or heterodimers of Jun (v-Jun, c-
Jun, JunB, and JunD), Fos (v-Fos, c-Fos, FosB, Fra1 and Fra2) or activating transcription factor (ATF2, 
ATF3/LRF1 and B-ATF) and basic region leucine zipper proteins. Stable heterodimers are formed 
between Jun and Fos as well as between the ATF-family members. Jun and ATF proteins can also form 
stable homodimers with themselves. The family of AP-1 proteins typically bind to the AP-1 site 
(TGAGTCA). Another site that is involved is the phorbol 12-O-tetradecanoate-13-acetate (TPA)-
responsive element (TRE: TGACTCA) that preferentially binds Jun-Jun and Jun-Fos dimers. The 
cAMP-responsive element (CRE: TGACGTCA) preferentially bind Jun-ATF and ATF-ATF proteins. Both 
these sites are palindromic and contain the same AP-1 half site 68. Several new bZIP proteins have 
been added to the AP-1 family on the basis of the DNA sequence specificity. These are the Maf 
proteins (v-Maf and c-Maf) and the neural retina specific gene product (Nrl) 50. These proteins can form 
heterodimers with the c-Jun and c-Fos proteins, which can then bind to the TRE, CRE, and an 
asymmetric DNA sequence, which consists of juxtaposed AP-1 and Maf half sites 50. Fos forms 
heterodimers with the Maf related proteins. v-Jun, JunB, and JunD cannot form these heterodimers with 
Maf related proteins although c-Jun can form heterodimers with Maf related proteins 50. Because of the 
interaction between c-Jun and the Maf related proteins novel bZIP proteins were identified, namely Jun-
dimerizing partners (JDPs) 1 and 2 50. These proteins can bind to both the TRE and the CRE.  The AP-
1 site is still in its infancy stage as the numbers of bZIP proteins are increasing resulting in an 
increasing number of possible heterodimers that can be formed. 
 
The abundance of the AP-1 proteins is important in the regulation of the AP-1 activity. Controlling the 
transcription of their genes is the most common mechanism for regulating the abundance of the AP-1 
proteins. In addition, regulation can also occur at the RNA level, via protein turnover and via regulating 
the activity of other proteins by posttranslational modification. MAPK phosphorylates the serines and 
threonines of the c-Jun amino-terminal activation domain, which reduces the ubiquitination of this 
protein and resulting in its degradation. The opposite can occur when c-Jun is phosphorylated on serine 
63 and 73 by c-Jun N-terminal kinase (JNK) resulting in an increase in stability 50. v-Jun on the other 
hand is more stable than c-Jun as it is a target for JNK-mediated phosphorylation 50. The 
phosphorylation of serine 63 and 73 by JNK has been found to increase the AP-1 sites transcriptional 
activity. It has been said that the phosphorylation step is required to allow the recruitment of the 
transcriptional coactivator cAMP response element-binding (CREB)-binding protein (CPB), allowing for 
transcriptional enhancement 50. Enzymatic histone acetyltransferase (HAT) activity is contained within 
CBP and its homolog p300, which are large cointegrator proteins that have a docking platform for many 
different transcription factor families. HAT activity functions in such a way that it shifts the chromatin 
structure of the transcription factor into a looser configuration allowing access too many factors such as 
basal or specific transcriptional factors leading to gene transcription 50. 
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1.6.8 The role of AP-1 
The AP-1 element is a very interesting element as it plays various roles in different cell systems. The 
AP-1 site has been implicated in regulating the basal levels of the GnRHR in αT3-1 cells as well as in 
GGH3 cells 14, 69. Duval et al. (1997) 14 found that if the AP-1 site of the mGnRHR was mutated it resulted 
in a 60% decrease in basal levels. Contradictory to these Cheng et al. (2000) 70 found that in the human 
GnRHR gene AP-1 does not play a role in basal promoter activity in αT3-1 cells. However, it does play 
a role in the decrease in human GnRHR promoter activity after GnRH treatment. They found that when 
αT3-1 cells were treated with GnRH it resulted in a decrease in GnRHR promoter activity, which was 
suggested to be most likely regulated via the PKC pathway 70. Using various mutations in the 5‘ flanking 
region they found an AP-1 binding site situated at  -1000/-994 within the human GnRHR 5‘ flanking 
region. When this AP-1 site was mutated it abolished the inhibition of the GnRHR promoter upon GnRH 
treatment. This implicates the AP-1 binding site in the down-regulation of GnRH 70. Electrophoretic 
mobility gel shifts (EMSA’s) performed with nuclear extracts that were not treated with GnRH resulted in 
only the c-Jun homodimer binding to the promoter, whereas nuclear extracts that were treated with 
GnRH resulted in both the c-Jun and c-Fos hetero- and homodimer binding to the promoter. A 
suggestion was that the possible mechanism for this GnRH-mediated inhibition could be due to the 
composition of the AP-1 isoforms and that c-fos may play an important role in mediating GnRH induced 
inhibition of the human GnRHR gene expression.  
 
Recently, experiments performed in transgenic mice expressing the GnRHR promoter that had 
mutations in the canonical AP-1 site (-336), showed that a loss in GnRH regulation of the mouse 
GnRHR promoter occurred. The results showed that an intact AP-1 site is important for GnRH 
responsiveness of the mouse GnRHR gene in vivo 42.  GnRH action on the GnRHR promoter appears 
to be species-specific as the sheep GnRHR promoter does not appear to contain an AP-1 consensus 
site 71. 
 1.6.9 Regulation of the GnRHR gene by steroids 
Researchers have found that in rat, sheep and cow estradiol increases the level of GnRHR mRNA and 
proteins in the pituitary 11, 72, 73, 74, 75. One group of researchers did however find that the GnRHR mRNA 
levels increased prior to the increase in estradiol leading to the conclusion that the prior decrease in 
progesterone was necessary in order for the up-regulation of GnRHR numbers to occur 76. 
 
Researchers have also found contradictory results depending on the cell line. For instance McArdle et 
al. (1992) 36 found that in αT3-1 cells estradiol stimulation resulted in a decrease in GnRHR numbers, 
while Turgeon et al. (1996) 43 found that in LβT2 cells, estradiol stimulation resulted in little effect on the 
endogenous GnRHR gene expression levels. In many mammals that were investigated researchers 
found that when high levels of progesterone were present resulting in a decrease in the GnRHR protein 
levels leading to a decrease in the responsiveness to GnRH in the pituitary 72, 77, 78. 
 
  
  
30
In αT3-1 cells it was found that when progesterone was administered in the presence of over-expressed 
PR isoform, an inhibition of the human GnRHR promoter activity occurred 91.  Cheng et al. (2001) 79 
showed that this negative effect occurred via a GRE/PRE (-535/-521). 
 
An interesting finding by Turgeon et al. (1996) 43 was that the endogenous GnRHR mRNA levels 
increased when stimulated with GCs in LβT2 cells. Further increases in the GnRHR mRNA levels were 
found when they pre-treated the LβT2 cells with GnRH 43. Consistent with this result; Maya-Nunez et al. 
(2003) 69 found that GCs directly regulated transcription of the mouse GnRHR promoter in GGH3 cells 
69. It is known that the mouse GnRHR promoter does not contain a classical GRE and that the 
glucocorticoid-responsiveness occurs via the AP-1 (-336) site on the mouse GnRHR promoter. 
Therefore, this suggests that in the presence of GCs, the liganded GR can interact with AP-1 proteins to 
increase GnRHR transcription 69.  
 
1.7 Previous work completed in this laboratory 
In previous research completed in this laboratory, studies were carried out on two nuclear receptor half 
sites termed site 1 (-15/-7) and site 2 (-244/-236) on the GnRHR promoter in αT3-1 cells 80.  When site 
1 was mutated it resulted in no significant effect on the basal transcriptional activity of the GnRHR 
promoter.  When site 2 was mutated a loss in basal activity was observed suggesting that site 2 is 
important in maintaining the basal levels of expression of the mGnRHR promoter.   
 
It was shown that while the mGnRHR promoter is upregulated by PKA, neither sites 1 or 2 are required 
for the PKA response in these cells. However, the results did suggest a modulatory role in the PKA 
response for the transcription factors Steroidogenic Factor-1 (SF-1) via both sites 1 and 2.  
 
1.8 The aim of this study 
This study aimed to carry out successful attempts to mutate two cis-elements; namely site 3 and the 
AP-1 site of the mGnRHR promoter using site-directed PCR mutagenesis.  Originally, this project was 
set out to determine whether or not SF-1 protein or AP-1 protein bound to the cis-elements in LβT2 
cells, site 3 or the AP-1 site of the mouse GnRH receptor promoter. Anti-SF-1 and anti-fos or anti-jun 
antibodies would be used to confirm if SF-1 protein or AP-1 protein formed a complex with site 3 or the 
AP-1 site in gel mobility shift assays. Another aim of this project was to determine whether 
glucocorticoids and GnRH regulate transcription of the GnRHR promoter via the AP-1 site or site 3 in 
LβT2 cells.  Other mGnRHR promoter-reporter studies were carried out by overexpressing the SF-1 
protein or PKA protein and determining which cis-element (site 3 or the AP-1 site) is involved for the 
increase in mGnRHR promoter transcription. 
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Chapter 2: Methods and Materials 
2.1 Oligonucleotides 
2.1.1 Oligonucleotide sequences. 
Oligonucleotides were synthesized and provided by Integrated DNA Technologies (IDT) (Whitehead 
Scientific, Cape Town, South Africa).  The two strands of the oligonucleotides shown below in mutated 
site 3 were used as PCR primers in site-directed mutagenesis, as well as for electrophoretic mobility gel 
shifts. These sequences correspond to the mouse gene in figure 1.  
 
Site 3: 
5‘ GGT   CCA   AGT   GTC   CTT   CCT    CAC   C 3‘ 
3‘       A  GGT   TCA   CAG   GAA   GGA   GTG   G 5‘ 
 
Mutant site 3: 
5‘ AAT  TAG  ACT  CCA  AGT  GTt    tTT   CCT    CAC  CTA  CGA  TA 3‘ 
3‘ TTA  ATC  TGA  GGT  TCA   CAa  aAA   GGA  GTG  GAT  GCT   AT 5‘ 
 
Note: The SF-1 binding site is underlined.  For mutant site 3, sequences within the SF-1 site and in 
bold correspond to those of the wild type site 3. Letters in lower case are the sites that were mutated. 
The SF-1 binding site is underlined. 
 
Nucleotides mutated were chosen on the basis of Horn et al. (1992) 81 where it was shown that 
mutation of two central C’s to T’s (upper strand) led to a loss of the SF-1 binding in vitro.   
AP-1: 
5‘ GGG   ATA   TTA   TGA   GTC   ACT   TTC   GA 3‘ 
3‘       C   TAT   AAT   ACT   CAG   TGA   AAG  CT 5‘ 
Mutant AP-1: 
5‘ GGG   ATA  TTA    gGA   aTt   cCT    TTC    GA 3‘ 
3‘       C   TAT   AAT   cCT    tAa  gGA     AAG   CT 5‘ 
 
Note: Sequences in bold and underlined are the AP-1 binding site. Sequences in bold, uppercase and 
underlined are the wild type AP-1 consensus site. Sequences in lower case are the mutated bases of 
the AP-1 DNA binding site.  
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2.1.2 Annealing of the single stranded oligonucleotides 
Equimolar ratios of the complementary single-stranded oligonucleotides were mixed with each other (10 
μl of a 1 mM solution of each in H2O) and incubated as follows: 88ºC for 2 minutes, 65ºC for 10 
minutes, 37ºC for 10 minutes and 25ºC for 5 minutes. The annealing mix was then chilled on ice.  The 
double stranded oligonucleotides were stored at -20ºC.  Electrophoresis on a 2% (w/v) agarose 
(Whitehead Scientific) gel in 1 X TAE 94 gel was carried out in order to check the integrity and annealing 
of the double stranded oligonucleotides by comparing their mobility to that of the single stranded 
oligonucleotides. 
2.2 Electroporation 
Electrocompetent cells (a gift from C.Langeveldt) were diluted in a 1:1 ratio in 10% (v/v) ice-cold 
glycerol. 40 μl of this chilled cell suspension was added to 1 ng plasmid DNA and transferred to the 
prechilled electroporation (1 mm gap) cuvette and subjected to an 1800 V electric pulse in a Savant 
GTF 100 Gene Transformer. After the electric pulse 1 ml SOC medium was added to the cuvette to 
wash out the cells in the electrode gap. The cells were then transferred into a culture tube and 
incubated for 1 hour at 37ºC at 225 rpm on a shaking incubator. The cells were plated out at different 
dilutions on LB-agar plates containing 50 µg/ml ampicillin. The plates were incubated at 37ºC 
overnight. 
2.2.1 Colony selection and glycerol stock preparation 
A sterile toothpick was used to pick the positive colonies, which were suspended in 20 µl sterile water. 
The tube containing the cell suspension was vortexed and 400 µl LB medium containing 50 µg /ml 
ampicillin was added. The cells were allowed to grow overnight at 37ºC at 200 rpm on a shaking 
incubator. 80 µl of an 80% (v/v) glycerol solution was added to the tube containing the overgrown cells 
and the mixture was vortexed. The tubes containing the cells mixed with glycerol was stored at -80ºC. 
2.3 Plasmid preparation 
2.3.1 Wizard Plus SV Minipreps DNA Purification System 
Mini-scale plasmid preparations were performed with the Promega Wizard miniprep kit.  The method for 
the minipreps was carried out as per manufacturer’s protocol, with a slight modification. Briefly, an 
inoculation loop was used to transfer bacterial cells from the glycerol stocks to a 10 ml LB medium 
containing 50 µg/ml ampicillin and cultured overnight at 37ºC with shaking at 200 rpm. The overnight 
culture was then centrifuged at ~11000 x g at room temperature for 5 min in a bench top microfuge. The 
supernatant was discarded. The cell resuspension solution 250 µl was added to the pellet which was 
thoroughly resuspended by pipetting. 250 µl cell lysis solution was then added to the mixture and the 
mixture was inverted 4 times. 10 µl alkaline protease solution was added to the inverted mixture to 
facilitate proteolysis and the mix was inverted a further 4 times and incubated for 5 min at room 
temperature. 350 µl neutralization solution was added to the mixture and mixed by inverting 4 times. 
The mixture was then centrifuged at ~11000 x g for 10 min at room temperature in a bench top 
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microfuge. The clear lysate was then decanted into a spin column and the spin column was centrifuged 
at top speed for 1 min at room temperature. The flow through was discarded. 750 µl wash solution 
(containing ethanol) was added to the spin column to wash away any contaminants and the column 
was centrifuged at ~11000 x g for 1 minute at room temperature. The flow-through was discarded. A 
second round of washing was performed by adding 250 µl of the wash solution into the spin column and 
centrifugation at ~11000 x g for 2 minutes at room temperature. The flow through was discarded. A 
modification was made to the final step. 100 µl of nuclease-free water was added to the spin column 
and the column was allowed to stand for 15 min before centrifugation at ~11000 x g for 1 min at room 
temperature. This step is performed in order to increase the yield. After centrifugation the DNA was 
stored at -20ºC. 
2.3.2 Qiagen plasmid maxi preparation 
The protocol used was in accordance with the manufacturer (Qiagen). Briefly, an innoculation loop was 
used to transfer cells from the glycerol stocks to a 5 ml LB medium starter culture, containing 50 µg/ml 
ampicillin. The starter culture was allowed to grow on a shaker for 6 hours at 200 rpm at 37ºC. 1 ml 
aliquots of the starter culture was inoculated into a 500 ml LB medium large culture, containing 50 µg/ml 
ampicillin and left to grow overnight on a shaker at 37ºC at 200 rpm. The bacterial cells were harvested 
by centrifugation (6000 x g for 15 minutes at 4ºC) in a Beckman JA-10 rotor. The supernatant was 
discarded and 10 ml of buffer P1 (containing RNase A) was added. The pellet was vigorously 
resuspended. 10 ml of buffer P2 was added and the mixture was gently (to ensure no shearing of the 
genomic DNA) inverted 4-6 times and incubated at room temperature for 5 minutes. 10 ml of pre-chilled 
buffer P3 was added the mixture and the mixture was mixed by gently inverting the mixture 4-6 times 
and allowed to incubate for 20 minutes on ice to enhance precipitation of genomic DNA, proteins, cell 
debris and SDS. The tube with the mixture was centrifuged at 20 000 x g for 30 min at 4ºC using a 
Beckman JA-20 rotor. A second round of centrifugation was carried out to make sure that all the 
precipitate was removed. A Qiagen-tip 500 was equilibrated by applying 10 ml buffer QBT and the 
column was allowed to run empty through gravity flow. The supernatant was applied to the column and 
it entered the resin by gravity flow. Once the column had run empty 2 x 30 ml washes with buffer QC 
took place to remove all contaminants. The DNA was eluted with 15 ml buffer QF. The DNA was then 
precipitated using 10.5 ml isopropanol at room temperature. The isopropanol was at room temperature 
in order to minimize salt precipitation. The precipitated DNA was then mixed and centrifuged at 15 000 
x g for 30 min at 4ºC in a Beckman JA-20. The supernatant was then carefully decanted and the DNA 
pellet was washed with 5ml room temperature 70% (v/v) ethanol. The DNA was then centrifuged for 10 
min at 15 000 x g in a Beckman JA-20. The supernatant was decanted and the pellet was air-dried for 
10min. The DNA pellet was re-dissolved in 500 µl TE buffer (10 mM Tris-HCl (pH7.5), 1 mM EDTA). 
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2.4 Mutagenesis 
2.4.1 Polymerase chain reaction (PCR) mutagenesis 
pLG containing the wild type mouse gonadotropin-releasing hormone receptor promoter (~700 base 
pairs) was cloned into the pGL2-Basic vector (Prof J.P. Hapgood, Department of Biochemistry, 
University of Stellenbosch). Various bases of pLG were mutated in the present study. These mutations 
were of the AP-1 site (at -336/-330 relative to the translational start site) and site 3 (-304/-296 relative to 
the translational start site). A PCR strategy was developed to mutate the AP-1 and site 3 sites using 
specially designed mutant primers (refer to above section). Firstly, 400 ng of pLG was subjected to PCR 
using the vector primer 5’ TGT ATC TTA TGG TAC TGT AAC TG 3’ (GL1 - sense) (Whitehead Scientific, 
Cape Town, South Africa), which is situated in the polylinker of the pGL2-basic plasmid, along with the 
anti-sense mutant primer. In a separate  reaction 400 ng of the pLG was also subjected to PCR but with 
a second vector primer 5’ CTT TAT GTT TTT GGC GTC TTC CA 3’ (GL2 - anti-sense) (Whitehead 
Scientific, Cape Town, South Africa), situated in the polylinker, 3’ to GnRHR promoter insert, along with 
the sense mutant primer. Reactions were made up to a final volume of 50 μl containing 1 μl of 10 mM 
dNTP, 5 μl of 10x buffer, and 3.4 μl of 25 mM MgCl2 (Promega) and the final volume was made up to 
50 μl with water. Lastly, 1 μl Taq Polymerase (Promega) was added to the mixture. PCR was performed 
using a Stratagene RoboCycler. The PCR cycle was as follows: 2.5 minutes at 90°C, followed by 1 min 
at 93°C, 1 min at 55°C, 1 min at 72°C for 35 cycles and a last cycle of 10 min at 72°C (see figure 17). 
 
The products from the two separate reactions were run on an analytical gel, which revealed the 
presence of two DNA bands both in the vicinity of ~350 bp. These fragments were gel purified by using 
a low melting preparative agarose gel (75 V for 30 minutes).  
 
2.4.2 Isolation of DNA fragments using preparative low melting agarose 
electrophoresis 
 
The preparative low melting agarose gels are methodologically the same as the analytical agarose gels 
(mentioned later) with the exceptions being the type of agarose that is used and a difference in the 
voltage and time of electrophoresis. Preparative gels were run at 75 V for duration of 30-45 minutes. 
After electrophoresis the preparative gels were analysed using a long wavelength ultraviolet light and 
the bands of interest were excised with a sterile scalpel. 
2.4.3 Purification of the DNA fragments from the preparative low melting 
agarose gel 
 
The spin column protocol of the manufacturer (Macherey-Nagel) was followed. Briefly, the fragments 
that were excised from the gel were placed in a sterile 1.5 ml microcentrifuge tube. The weight of the 
gel-excised fragment was determined. For every 100 mg of gel, 300 μl of buffer NT1 was added to the 
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mixture and the mixture was incubated at 50°C for 10 minutes with occasional vortexing. The sample 
was then loaded onto a NucleoSpin column (Macherey-Nagel) and this column was placed in a 2 ml 
centrifuge tube. The tubes containing the column together with the sample were centrifuged for 60 
seconds at 6 000 x g at room temperature. The flow-through was discarded. 700 μl buffer NT3 was 
added to the spin column and the tubes were centrifuged at ~15000 x g for 60 seconds at room 
temperature. The flow through was discarded. A second round of 700 μl buffer NT3 was added to the 
spin column and the tubes were centrifuged at ~15000 x g for 60 seconds at room temperature and 
the flow-through was discarded. The NucleoSpin column was centrifuged again to remove all excess 
buffer NT3 as residual ethanol inhibits subsequent reactions. The NucleoSpin tube was placed in a 
fresh 1.5 ml microfuge tube and 50 μl elution buffer NE was added and the tube was centrifuged for 60 
seconds at ~15000 x g at room temperature. The purified DNA fragments were contained in the flow-
through and were stored at -20°C until further use. 
2.4.4 PCR fusion reaction 
Fusion of the two purified gel fragments (that were generated by PCR using primers GL1 sense and 
mutated antisense primers for one reaction, and mutated sense primers plus antisense GL2 primers in 
the other reaction) was carried out. The bases around the mutation site in the two fragments are 
complementary to each other and would thus anneal and act as primers for the fusion reaction. Equal 
volumes of the fragments 1 and 2 were added in the fusion reaction. The fragments were added to a 
final volume of 50 μl in the presence of 1 μl dNTP (10 mM), 5 μl 10 x buffer, 1 μl GL1 (20 μM), 1 μl 
GL2 (20 μM), 3.4 μl MgCl2 (25 mM), and 1 μl Taq Polymerase. The samples were place into the 
Stratagene RoboCycler and subjected to 30 cycles. The cycles were as follows: 30 seconds at 94°C 
and 30 minutes at 72°C. The fusion reaction was analyzed on an agarose gel (100 V for 20 minutes) 
and showed a product of ~700 bp. A preparative low melting gel (75 V for 30-45 minutes) was carried 
out on the PCR product and the DNA fragment of ~700 bp was purified.  A few additional bands were 
observed on the analytical gel, which could be due to non-specific binding when the PCR fusion 
reaction was carried out. 
2.4.5 Restriction digests 
An approximately 700 bp fragment was excised out of the wild type LG construct, which contained the 
wild type promoter. A fragment of the same size which contained all the same bases except for the 
mutated AP-1 site or the mutated site 3 was reinserted into the pLG construct.  Restriction digests of 
the 700 bp PCR product was carried out with the appropriate restriction enzyme and buffers 
(Boehringer Mannheim, Roche) to digest DNA. The sites where the restriction enzymes cut were 
naturally found on the wild type construct.  The restriction enzymes Kpn1 and Bgl II were carried out in 
their appropriate buffers (buffer L and buffer H, respectively) (part of kit bought from Boehringer 
Mannheim, Roche) and added to both the mutated insert and the vector. The restriction digest reaction 
was performed in a total volume of 30 μl. The restriction enzymes were supplied in a glycerol solution; 
therefore the volume of enzyme added never exceeded one-tenth of the final volume. The buffers 
supplied were added as a 10 X dilution to the final volume. Digest samples were incubated overnight at 
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37°C. Double digests were performed on separate days, as the optimal salt concentrations were 
different. The first restriction enzyme was performed in a low salt concentration overnight and the 
second restriction enzyme in a high salt concentration. These conditions and the salt concentrations 
were also taken into consideration for the vector, LG, (2.5 µg/μl) restriction digests, which was carried 
out in a total volume of 20 µl. This was performed in order to excise the wild type insert, so that the 
mutated insert could be ligated back into the vector.  After digestion, the mixture containing LG 
digestion products was digested with calf alkaline phosphatase to remove the 5‘ phosphate groups, in 
order to prevent self ligation of the vector in the subsequent ligation reaction. Briefly, the vector digest 
mixture was made up to a total volume of 40 µl with the following: 10 X buffer (10 X dilution), and calf 
alkaline phosphatase enzyme (20 x dilution). The mixture was incubated for 1.50 hours at 37°C. 
Digestion reactions were terminated by adding an equal volume of 2 X concentrated gel-loading buffer 
(3% glycerol, 0.02 M Tris (pH 6.8) and 0.1% (w/v) bromophenol blue) and analysed on an analytical 
agarose electrophoresis gel. The digestion products were then run on a preparative gel and the large 
band corresponding to the vector part of LG was excised. This was to make sure that the small 
fragment (the wt GnRHR promoter fragment) was not present for the subsequent ligation step (see step 
2.4.7). 
2.4.6 Analytical agarose gel electrophoresis 
A 1% agarose gel was prepared (the percentage depends on the size of the fragments). The agarose 
gel was used to determine the size of the bands after restriction digestion. Preparative and analytical 
agarose gel electrophoresis of DNA fragments were performed according to the protocols of Sambrook 
et al. (1989) 82. Briefly, Agarose powder (Sigma) was weighed in a 100 ml conical flask. The agarose 
powder was dissolved in 1 X TAE (40 mM Tris, 30 mM Acetate, 2 mM EDTA (pH 8)). The liquid agarose 
was heated until the agarose had dissolved. Once the mixture had cooled 10 mg/ml ethidium bromide 
was added to a final concentration of 0.5 µg/ml to enable the visualization of the DNA fragments under 
ultraviolet light. The gel solution was poured into a horizontal gel-moulding chamber (air bubbles were 
removed) and a suitable comb was placed in the chamber. The gel was allowed to set for 30 minutes at 
room temperature. When the gel was set the comb was removed and the gel chamber was placed into 
a horizontal electrophoresis chamber and a 1 X TAE running buffer was poured into the chamber to 
cover the gel. DNA containing the 1 X gel loading buffer (9 μl sample + 1 μl gel loading buffer 
containing glycerol) was loaded into the wells using a pipette. The gel was allowed to run for 30 minutes 
at 100 V (or until the loading dye had travelled to about three quarters the length of the gel). The DNA 
bands on the agarose gel were visualized on a UV transilluminator. Bands that appeared were bright 
and were caused by the ethiduim bromide in the solution, which intercalated with DNA and absorbed 
the UV radiation. The marker that was used was the EZ Load 100 bp PCR Molecular Ruler (AEC 
Amersham) resulting in bands corresponding to 100 bp, 1000 bp and 3000 bp (This marker was used 
when analysing PCR products). For restriction digest analysis a 0.13 µg/µl 100 bp ladder (Promega) 
was used with DNA fragment of sizes: 100 bp, 200 bp, 300 bp, 400 bp, 500 bp, 600 bp, 700 bp, 800 bp, 
900 bp, 1000 bp and 1 500 bp. 
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2.4.7 Ligation 
The reagents and solutions used for the ligation process were supplied with the pMOS kit (Roche). A 
molar ratio of 1:5 (vector: insert) was used.  Insert (60 ng) (which contained the mutation of interest) 
was ligated into 120 ng of vector prepared in 2.4.5 in a final reaction volume of 20 μl, in the presence of 
2 μl 10 X ligase buffer (1 U/mL) (Boehringer Mannheim, Roche), 2 μl T4 DNA ligase enzyme 
(Boehringer Mannheim, Roche). The mixture was incubated at 4°C overnight.  
2.4.8 Transformation of ligated DNA into MosBlue cells 
5 ng of the ligation reactions was transformed into 20 μl competent MosBlue cells (Roche Molecular 
Biochemicals). The mixture was incubated for 30 minutes on ice with the occasional swirl. The cells 
were heat shocked for 40 seconds at 42°C in a water bath; allowing DNA to enter the cell. The mixture 
was then placed immediately on ice for 2 minutes and 80 μl of room temperature SOC medium 82 was 
added. The mixture was placed on a shaker at 200 rpm for 1 hour at 37°C. The transformed cells were 
plated out on LB agar plates containing 50 µg/ml ampicillin and allowed to grow overnight at 37°C. 
2.4.9 Screening of colonies 
A PCR screening method using GL1 and GL2 primers, which are situated in the polylinker, was used. 
Screening of colonies is important to make sure that the colonies that have formed on the LB agar 
plates after transformation actually contain the insert of correct size. Colonies were picked off the LB-
agar plate with a sterile toothpick and used to inoculate 20 μl sterile water and the mixture was vortexed 
to resuspend the colony. 5 μl of this bacterial suspension was used for PCR colony screening. The final 
volume for the PCR colony screening was 25 μl, which contained 10 mM dNTP, 10x buffer, 20 μM GL1, 
20 μM GL2, 25 mM MgCl2, and 1 μl Taq Polymerase (5 U/μl) (Promega) and made up to 25 μl with 
water. The mixture was mixed and 80 μl mineral oil was added. The PCR cycle was as follows: 35 
cycles of: 1 minute at 94°C, 1 minute at 50°C, 1 minute 72°C, followed by one step of 10 minutes at 
72°C after the last cycle. 
The products were run on a 1% analytical agarose gel (100V; 30 minutes) and the rest of the bacterial 
suspension was made into glycerol stocks. Positive colonies that were identified from the agarose gel 
were grown up using Wizard Plus SV Minipreps DNA Purification System (Promega). 0.1 µg DNA was 
submitted for DNA sequencing at the DNA Sequencing facility, Department of Genetics, University of 
Stellenbosch, Stellenbosch using GL1 and GL2 primers. 
2.5 Labelling of double-stranded oligonucleotides with Polynucleotide kinase. 
The protocol for labelling was carried out as per manufacturers protocol (Roche Molecular 
Biochemicals). Briefly, 10 ρmoles of double stranded oligonucleotide was mixed with 2 µl 10 x 
polynucleotide kinase (PNK) labelling buffer (part of the kit from Roche) and 20 ρmoles [γ-32P] ATP 
(AEC Amersham). One unit of PNK enzyme was added and the volume was made up to 20 µl with 
water. The mixture was incubated for 30 minutes at 37°C on a heating block. The DNA mixture reaction 
was stopped with 2.5 µl 0.2 M EDTA. The volume was made up to 100 µl with TE buffer 82. The labelled 
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mixture was passed through a 1 ml G50 Sephadex (Pharmacia) spin column, which was equilibrated 
with TE buffer, which separated all the unincorporated nucleotides. Cherenkov counts obtained in a 
Beckman Scintillation Counter determined the labelling efficiency and specific activity of the probes. 
The specific activity was usually in the region of 107 - 109 dpm per µg labelled DNA. 
2.6 Electrophoretic Gel Mobility Shift Assays. 
The assay protocol for site 3 was adjusted from the method described by Horn et al. (1992) 81 and 
Sadie et al. (2003) 80. Incubations for the site 3 studies were performed in final buffer concentrations of 
58 mM NaCl, 0.16 mM EDTA (pH 8), 1 mM DDT, 0.4 mM PMSF, 0.25 mM EGTA, and 10 mM Tris-Cl 
(pH 7.5). A cocktail was prepared by adding 0.7 μl of the above mentioned buffer together with 1 μg/μl 
poly-dI-dC, which acts as a non-specific DNA competitor, and 20 μg/μl BSA (Roche Molecular 
Biochemicals) per tube reaction. 1.5 µl of the cocktail was added to 1 μl labelled oligonucleotide and 2 
μg/μl nuclear extracts to form a final volume of 4 µl. 
 
AP-1 studies were carried out according to the Strahl et al. (1997) 64 method.  Incubations for the AP-1 
studies were performed in final buffer concentrations of 1.4 mM EDTA, 0.23 mM DDT and 10 mM Tris-
Cl (pH 8). 0.8 µl of the above mentioned buffer was added to 0.5 µl Poly dI-dC (Roche Molecular 
Biochemicals) per tube of reaction. 1 µl of this cocktail was added to 1 µl labelled oligonucleotide and 2 
µg/µl nuclear extract. The final incubation volume was 20 µl. All reactions were performed with 1 µl (0.1 
ρmoles) radiolabelled double-stranded oligonucleotide probe (150 000 to 250 000 cpm) and 1.5 µl (1 to 
2 µg) of LβT2 nuclear extracts or αT3-1 nuclear extracts. The proteins were incubated for either 10 
minutes (SF-1 studies) or 20 minutes (AP-1 studies) on ice in the presence or absence of various 
antibodies, after which radiolabelled probe was added followed by an additional 10 minutes (SF-1) or 
20 minutes (AP-1) incubation at room temperature. For antibody assays, 1 µl of undiluted antibody or 
antiserum was added to the mixture. In the case of rabbit pre-immune serum, 1 µl of a 1:28 dilution was 
added to the mixture (mixture contained no specific antibody). Pre-immune serum is added to make 
sure that the binding observed in the antibody reaction is specific and that other antibodies and proteins 
present in the rabbit pre-immune serum cannot bind to the specific site. For 30% non-denaturing PAGE, 
the polyacrylamide mixture (29:1 acrylamide:bisacrylamide) was prepared as follows:14,5 g ultra-pure 
acrylamide (USB) and 1 g N,N‘-methylenediacrylamide (bisacrylamide, Merck, electrophoresis grade) 
was dissolved in sterile deionized water to a final volume of 100 ml. This mixture was filtered using 
Whatman no.2 filter paper. Thereafter the gels were poured using 6.7 ml 30% acrylamide mix, 32.5 ml 
MilliQ water, 400 μl 50x TAE, 70 μl TEMED and 400 μl (w/v) and 10% ammonium persulphate and 
allowed to set overnight at 4°C. Polyacrylamide gels were electrophoresed using a BioRad Protean II xi 
gel apparatus. Before loading of the samples the gels were pre-electrophoresed at 100 V for 2 hours in 
1 x TAE buffer at room temperature. After the incubation of the samples, the samples were loaded onto 
the gel and the complexes resolved by electrophoresis at 100 V for 3.5 - 4 hours in fresh 1 x TAE buffer 
at room temperature. Gels were then transferred to blotting paper, wrapped in saranwrap and dried on 
a vacuum gel dryer, allowing the gel to dry under heat for 30 minutes followed by exposure to Hyperfilm 
(Amersham) at -80°C. 
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2.7 Tissue Culture 
2.7.1 Cell culture conditions 
Dr Pamela Mellon from the University of California, San Diego, California, kindly supplied LβT2 and 
αT3-1 pituitary gonadotrope cells. The cells were grown in Dulbecco’s modified Eagle Medium (DMEM) 
(Sigma) (4.5 g/L glucose) with 10% fetal calf serum (Adcock Ingram) and 50 IU/ml streptomycin 
(GibcoBRL). The cells were maintained in 75 cm2 cell culture flasks (Laboratory and Scientific 
Equipment Company (LASEC) at 37°C with 90% humidity and 5% CO2. Cells were then plated out in 24 
well plates (AEC Amersham, Nunc) at the required cell density (stated below all experiments). 
2.7.2 Transfection of αT3-1 cells with the Polyethylenimine method 
A 10 mM polyethylenimine (PEI) (Roche) stock was prepared in a sterile Greiner tube at pH 7. The ratio 
of DNA to PEI (wt/wt) was 1:10.  Volumes for transfections were made up to 50 µl with 150 mM NaCl 
resulting in a final concentration of 150 mM. In preparation for transfections two sterile microcentrifuge 
tubes labelled D1 and P1 were used. D1 tubes contained 0.65 μg/ μl LG, 0.66 μg/ μl β-gal and 150 mM 
NaCl in a final volume of 250 μl. The P1 tubes contained 150 mM NaCl and 4.5 μl PEI in a final volume 
of 250 μl. Each tube was mixed vigorously and incubated for 10 minutes at room temperature. The 
solutions in the P1 and D1 tubes were then added together in a drop-wise fashion (PEI to DNA), 
vortexed and incubated again for 10 minutes at room temperature. Cells were plated out the previous 
day into a 12 well plate at two different densities: 1x105 and 2x105 cells per well. 1 ml of medium 
containing 10% serum was added to each well of the 12 well plates. After 10 min the medium 
(containing 10% serum) was removed and fresh medium containing 10% serum (1 ml/well) was added. 
100 µl of the mixture (P1 and D1) was added to each well in a drop-wise fashion. Plates were incubated 
at 37°C overnight. The following day the medium was removed and the wells were washed with 1 ml 
PBS (pH 7.3) in order to wash away any excess medium and the cells were harvested. 100 µl lysis 
buffer (Promega) was added to each well and cells were allowed to stand for 15 minutes at room 
temperature. Plates were then stored at -20°C overnight.  
2.7.3 Transfection of LβT2 and αT3-1 cells with the DEAE method 
LβT2 and αT3-1 cells were plated out 24 hours prior to the transfection studies. The densities for 
experiments are stated in the legends below each experiment in the results and discussion section. The 
transfection medium contains 2.5% serum in DMEM, which was prepared first, since higher serum 
concentrations could lead to the precipitation of DEAE-dextran (1 part serum to 3 parts medium).  
Chloroquine was added to the transfection medium to a final concentration of 100 µM. The transfection 
solution was warmed to 37 °C in a water bath. This solution was added to the different microcentrifuge 
tubes containing varying amounts of DNA (ranging 0.75 - 1.5 μg) diluted in distilled water. 10 mg/ml 
DEAE-dextran stock solution was warmed to 37 °C and mixed by inversion. 10 mg/ml DEAE (1.25 μl 
per single well) was added to the transfection solution. The volume of DEAE-dextran was calculated 
depending on the volume of DNA and the amount of DEAE to be 1.25 x number of the well, to give a 
final volume 500 μl, resulting in a final concentration of DEAE-dextran of 100 µg/ml. The medium in the 
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12-well plates were aspirated and replaced with the appropriate volume (500 µl/well for a 12 well plate) 
of 37 °C DEAE-dextran / DNA supplemented transfection medium. Cells were incubated for 1 hour at 
37 °C. Thereafter, the transfection medium was aspirated and replaced with 1 ml of a solution 
containing 10% (v/v) dimethyl sulfoxide (DMSO) in phosphate buffered saline (PBS), which had been 
pre-warmed to 37°C. Cells were then incubated at room temperature for ~ 5 minutes. The DMSO / PBS 
solution was removed and the cells were washed with 1 ml PBS to remove the DMSO/PBS solution. 
PBS was removed and 1 ml medium (Dulbecco’s modified eagle medium (DMEM) + 10% fetal calf 
serum (FCS) was added. The cells were incubated overnight at 37°C. The following day the medium 
was removed from the plates and washed with 1ml PBS (pH 7.3).  The cells were harvested using 100 
µl lysis buffer (Promega) and the plates containing the cells were allowed to stand for 15 minutes at 
room temperature. Plates were then stored at -20°C overnight. 
2.7.4 Transfection of LβT2 and αT3-1 cells with lipofectamine 
LβT2 and αT3-1 cells were plated out 24 hours prior to the transfection studies. The densities that were 
required are stated in the legends below the experiments in the results and discussion section. On the 
day of transfection studies the medium was removed from each well and replaced with 500 μl medium 
containing 10% FCS to each well of the plate. A mixture containing DNA and lipofectamine was 
prepared as follows: 2 microcentrifuge tubes were used, 1 tube was for DNA + medium (100 µl/well) 
and the other for medium + lipofectamine (Sigma) (100 µl/well). For every 1 µg of DNA, 1 µl 
lipofectamine was used (1:1 ratio). Depending on the volume of DNA required lipofectamine was added 
to medium and allowed to stand for 5 minutes at room temperature (various amounts required therefore 
see legends of experiments). DNA (see legends for volumes) + medium was added to the lipofectamine 
+ medium tube and allowed to incubate for 20 minutes at room temperature. 200 μl of the mixture 
containing DNA and lipofectamine was added to each well of the plate containing 500 μl medium in a 
drop wise fashion.  Plates were incubated at 37°C, overnight. The following day the cells were 
harvested after removing the medium and washing once with 1 ml PBS (pH 7.3) to each well, in order to 
wash away any excess medium. 100 µl lysis buffer (Promega) was added to each well and cells were 
allowed to stand for 15 minutes at room temperature. Plates were then stored at -20°C overnight. 
2.7.5 Transfection of LβT2 cells with fugene 
LβT2 and αT3-1 cells were plated out 24 hours prior to the transfection studies. The densities that were 
required are stated in the legends below the experiments in the results and discussion section. The 
method for fugene (Roche) was followed per manufacturer’s instructions.  The following day the 
medium was changed the and fresh pre-warmed (37°C) medium containing 10% FCS was added to 
each well of the plate. The required amount of DNA was added to a microcentrifuge tube (labelled 1) 
(see legends of experiments for volumes). The required amount of DMEM was added to a 
microcentrifuge tube (labelled 2). Fugene was allowed to reach room temperature. Fugene (a volume 
equal to twice the total amount of DNA in µg) was added to DMEM, directly to the centre of the 
microfuge as fugene will adhere to the sides of the microfuge and allowed to incubate for 5 minutes at 
room temperature. 
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The DMEM + fugene (tube 2) was added to DNA (tube 1) and incubated for 30 minutes at room 
temperature as this allowed DNA and fugene to form complexes. The growth medium of the cultured 
cells was replaced with fresh growth medium that contained 10% FCS. The transfection medium (50 
µl/well) was added in a drop-wise fashion to the cells containing the fresh growth medium and allowed 
to incubate at 37°C, overnight.  The following day the cells were harvested after removing the medium 
and washing each well once with 1 ml PBS (pH 7.3), in order to wash away any excess medium. 100 µl 
lysis buffer (Promega) was added to each well and cells were allowed to stand for 15 minutes at room 
temperature. Plates were then stored at -20°C overnight. 
 
2.8 Luciferase studies 
For all experiments e.g PEI, DEAE, lipofectamine and fugene, plates were removed from -20°C and 
allowed to thaw at room temperature. Once the plates were fully thawed 20 µl of the lysate of each 
well was removed and placed into a microtiter plate (Nunc) for luciferase assays. 100 µl luciferase 
assay substrate (Roche Molecular Biochemicals) was dispensed into each well. The assay substrate 
binds to the luciferase enzyme produced by the luciferase gene, which results in fluorescence; 
therefore a reading can be obtained on the labsystems luminoskan RS luminometer. 
 
2.9 β-galactosidase studies 
β-galactosidase (β-gal) assays were performed on all transfection studies e.g. PEI, DEAE, 
lipofectamine and fugene, as it acts as a transfection efficiency. A 50 X dilution of the Galacto-star 
substrate (Promega) was prepared (1 µl galactone to 49 µl diluent). Plates were removed from -20°C 
and allowed to thaw. Once the plates were completely thawed 20 µl of the lysate of each well was 
placed into a microtiter plate and used for β-gal assays. 100 µl/well of the 50 X diluted β-gal substrate 
was dispensed into each well and allowed to stand for 1 hour in the dark before the plates were read 
on the labsystems luminoskan RS luminometer.  Data were normalized by dividing the luciferase 
values by the β-gal values. 
2.10 Statistical analysis 
Luciferase and β-gal assay results were graphically analysed with GraphPad PRISMTM version 4 
software from GraphPad Software Incorporation.  The data was analysed with one-way ANOVA, with 
either Dunnett's post-test (when comparing all values to a single control) or Bonferroni’s post-test (when 
comparing all values to each other).   
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Results and Discussion 
3.1 Nuclear proteins from LβT2 cells recognize site 3 and the AP- 1 site on the 
GnRHR promoter in vitro 
3.1.1 Gel mobility shift assays 
Two SF-1 regulatory cis-elements are present on the GnRHR receptor promoter. Recently a novel third 
putative site, site 3, with unknown function was detected by sequence analysis in our laboratory. Site 3 
(-304/-296) has a similar consensus sequence as two other established SF-1 binding sites (site 1: -15/-
7 and site 2: -244/-236, respectively) found on the mouse GnRH receptor promoter (see figure 1). 
Therefore, this specific region of the promoter was tested to see whether nuclear extracts from the 
LβT2 cell line contain SF-1 protein and if specific binding occurs to this sequence in vitro. In addition, 
since the AP-1 site on the mouse GnRH receptor promoter (see figure 1) was previously shown to bind 
c-Jun and c-Fos proteins from nuclear extracts of GGH3 cells this lead to the investigation to whether 
these AP-1 proteins from the nuclear extracts of LβT2 cells could bind to the AP-1 consensus site.  
 
Firstly, sense and antisense oligonucleotides representing the element of interest were designed, 
annealed, radioactively labelled and used as probes in gel mobility shift assays. The theory behind this 
assay is that protein-DNA complexes migrate through a non-denaturing polyacrylamide gel according to 
the size, charge and conformation of each individual complex.  If protein binds to the specific site it 
significantly retards the migration of the fragment through the gel. The DNA is then “shifted” because of 
the protein binding. Visualization of the DNA-protein complexes can be seen on an autoradiograph due 
to the radiation from the DNA. DNA-specificity studies of the protein in the complex can be carried out 
by co-incubating excess non-labelled DNA competitors. Examples of DNA competitors can either be the 
same DNA fragment as the radiolabelled probe, or other sites on the promoter can be used. In order to 
identify the protein binding to the DNA element of interest antibodies targeted against specific proteins 
were used. Therefore, it is important to know what type of proteins could be involved in binding to the 
particular DNA element.  Antibodies can cause two different types of results depending on the type of 
antibody that is used i.e. an ablation of shift or a supershift. An ablation of shift results when the 
antibody recognizes the DNA-binding domain of the protein thereby inhibiting the protein from binding 
to DNA leading to no complex formation. A supershift on the other hand results when the antibody can 
recognise the protein while in complex with the DNA.  
 
A radioactively labelled oligonucleotide probe of site 3 was prepared and used in gel mobility shift 
assays, together with nuclear extracts from LβT2 cells and the SF-1 antibody. A negative control was 
also used which was rabbit pre- immune serum. 
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Figure 9: Autoradiograph of a gel mobility shift assay performed with the radiolabeled site 3 probe. For 
all lanes 1-2 μg of protein was used. Lane 1 contains nuclear extracts from αT3-1 cells. Lane 2 contains 
nuclear extracts from the LβT2 cells. Lane 3 contains nuclear extracts from LβT2 cells together with the 
SF-1 antibody. Lane 4 contains LβT2 nuclear extracts plus rabbit pre-immune serum. Arrows represent 
complexes containing SF-1, Nur77 protein or free probe. 
 
The SF-1 antibody used in this experiment is directed against the DNA binding domain of SF-1 resulting 
in the antibody recognizing the DNA-binding domain of the protein thereby inhibiting the protein from 
binding to DNA, which lead to no complex formation.  
 
Figure 9 shows that the SF-1 protein from both the LβT2 and αT3-1 gonadotrope cell lines binds to site 
3.  When the SF-1 antibody was present it caused an ablation of shift confirming that the protein that 
binds to site 3 is SF-1 (compare lanes 2 and 3). The reason why the cell line αT3-1 cells were used in 
this experiment is because it has previously been established that SF-1 protein is expressed in this cell 
line and binds to SF-1 sites 1 and 2 of the mGnRHR promoter 80.  This experiment also shows that 
there is more SF-1 protein in αT3-1 cells than in LβT2 cells as shown by the relative intensity of the SF-
1 bands. Another band that appears on the autoradiograph is that of Nur77 as deduced by others in the 
laboratory.   
SF-1 
Nur77 
Free probe 
        1       2        3        4 
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Figure 10: Autoradiograph of a gel mobility shift assay performed with the radiolabelled AP-1 probe.  
Lane 1 contains the probe in the absence of nuclear extracts. Lane 2 contains nuclear extracts from 
the LβT2 cells. Lanes 3 and 4 contain nuclear extracts from LβT2 cells together with the c-Fos 
antibody. Lane 5 contains LβT2 nuclear extract plus rabbit pre-immune serum. Arrows show 
complexes containing AP-1 protein and free probe. 
 
This band is known to contain Nur77 as Sadie et al. (2003) 80 investigated this band and found that 
performing similar experiments as that mentioned above using Nur77 antibody resulted in the band 
disappearing.  From the autoradiograph in figure 9 it is interesting to point out that there seems to be 
more Nur77 in LβT2 cells than in αT3-1 cells (compare lanes 1 and 2).  
 
Figure 10 shows that nuclear proteins from the LβT2 cells also bind to the AP-1 site of the mouse 
GnRH receptor promoter (compare lanes 1 and 2). If c-Fos were present in the nuclear extracts and c-
Fos antibody was added it would retard the migration and result in a supershift. When c-Fos antibody 
was added to the LβT2 nuclear extracts it did not cause a supershift of the DNA-protein complex. Thus 
it is possible that c-Fos is not present in the nuclear extracts or is present but fails to bind to the AP-1 
site in vitro under these conditions.  The former is most likely the case since the results from the 
literature suggests that c-Fos is not present in LβT2 cells in the absence of stimulation with GnRH 70. 
Experiments were carried out by researchers 83 using micro-array analysis in LβT2 cells. Researchers 
found that after 1 hour of GnRH stimulation that c-Jun and JunB mRNA levels increase although JunD 
mRNA levels remained unchanged 83.  They also found that when they stimulated LβT2 cells with 
GnRH the expression levels of FosB and c-Fos increased 83. Therefore, an experiment with the 
stimulation of LβT2 cells with GnRH should be carried out to investigate whether the c-Fos protein 
levels would increase and result in detectable binding to the AP-1 site.  It is possible that other proteins 
such as c-Jun bind to the AP-1 site and further experiments will have to be carried out to confirm this.  
AP-1 
Free probe 
1 2 3 4 5
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Figure 11: Autoradiograph of a gel mobility shift assay performed with LβT2 nuclear extracts and the 
AP-1 probe, in the absence and presence of varying concentrations of unlabelled competitor 
oligonucleotides. Competitors were used at 10-, 100-, and 1000-fold molar excess. Lane 1 contains the 
probe in the absence of nuclear extracts. Lanes 2, 6 and 10 contain nuclear extracts from the LβT2 
cells in the absence of unlabelled competitive DNA. Lanes 3-5 contain nuclear extracts from LβT2 cells 
together with 10-, 100-, and 1000-fold molar excess, respectively of unlabelled wild type AP-1 probe 
(wtAP-1). Lanes 7-9 contain nuclear extracts from LβT2 cells together with 10-, 100- and 1000-fold 
molar excess, respectively of unlabelled mutant AP-1 probe (mAP-1). The arrows denote the AP-1 
protein-DNA complexes or the free probe. 
 
To determine the DNA-specificity of the protein(s) that bind to the AP-1 site, competitive studies of the 
AP-1 probe were carried out as shown in figure 11. In lanes 3-5 different molar ratios of unlabelled wild 
type AP-1 probe were added. Both 100- and 1000-fold molar excess of unlabelled wild type AP-1 probe 
resulted in the complete disappearance of the band. However, when unlabelled mutant AP-1 was 
added it still competed the bands away with 100- and 1000- fold molar excess.   This shows that the 
protein(s) in the complex do not require the bases that are mutated. The AP-1 bases (wt: TGA GTC 
ACT) that were mutated for this study were GGA ATT CCT (bold letters are the bases that were 
mutated and the site that is underlined is the binding site). This mutation of the AP-1 site was also 
carried out by Maya-Nunez et al. (1999) 17 in studies performed in GGH3 cells 17.  In these cells these 
researchers found that c-Fos and c-Jun bind to the AP-1 recognition element and when the AP-1 site 
was mutated a disruption of binding occurred 17.  The difference between these researchers 17 
experiments and the experiments performed in this study is that Maya-Nunez et al. (1999) 17 stimulated 
wtAP-1              mAP-1 
AP-1 
Free probe 
1  2   3   4  5   6   7    8   9  10 
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the cells with dexamethasone for 12 hours before running electrophoretic studies. In the current study 
nuclear extracts were prepared from cells untreated with dexamethasone.  Thus it is possible that 
dexamethasone increases the amount of AP-1 protein allowing for easier detection compared to when 
unstimulated cells were used.  Secondly, the binding observed in GGH3 and not in LβT2 cells could be 
cell specific.  
 
It is possible that the protein-DNA complex observed in figure 11 consists of c-Jun homodimers.  A 
possible explanation for the binding of the c-Jun homodimers is that the homodimers do not require the 
bases that were mutated on the AP-1 site to be present. To my knowledge there has not been a paper 
published on the AP-1 sites that are important for the binding of c-Jun or c-Fos.  Other proteins such as 
CREB and SF-1 can also interact with the AP-1 transcription proteins.  Therefore, it is possible that the 
c-Jun protein is binding as a homodimer or with other proteins such as CREB or SF-1. 
 
3.2 Regulation of the GnRHR promoter gene by different cis-elements 
and under different conditions 
3.2.1 Optimisation of assay 
The role of the -304/-296 (site 3) and -336/-330 (AP-1 site) in basal and in induced expression of the 
mouse GnRHR gene in LβT2 cells was investigated.  Before transfection studies were carried out 
optimisation studies of the wild type GnRHR promoter were carried out in order to determine which 
transfection procedure would be optimal.  The optimal conditions would be a detectable or as high as 
possible Relative light units (RLU’s).  Luciferase and β-gal values that were clearly distinguishable from 
background would be acceptable. 
 
 1 2 3 4 5 6 
Transfection 
method 
lipofectamine PEI PEI PEI PEI PEI 
μg LG 1 1 0.5 0.5 1 0.5 
μg β-gal 0.5 0.5 0.25 0.25 0.5 0.25 
Table 1: Amounts of DNA transfected into αT3-1 cells.  Experiment was carried out in duplicate. 
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Figure 12: The effect of varying amounts of wild type LG and β-gal expression vector, ratios of DNA to 
PEI, and cell density on the expression of GnRHR promoter reporter using polyethylenimine (PEI) 
transfection method. Columns 1, 3 and 5 had a cell density of 1x106 cells/well whereas columns 2, 4 
and 6 had a cell density of 2x105 cells/well. Values of 1 μg or 0.5 μg wild type LG were used while 0.5 
μg or 0.25 μg β-gal expression vector was used.  In the first column lipofectamine was used as the 
transfection method. In columns 2-6 the PEI method was used as the transfection method.  The PEI: 
DNA ratio for the columns 2, 3 and 4 is 10:1.  In column 5 and 6, 1 μg or 0.5 μg wild type LG was used 
together with 0.5 μg or 0.25 μg β-gal expression vector with a DNA: PEI ratio of 5:1.  Luciferase values 
were shown in the graph as no β-gal values were obtained. This graph is a result of combined data 
from two experiments, each point in duplicate. Standard errors are shown. 
 
Firstly, the polyethylenimine (PEI) method was investigated in order to determine if this transfection 
procedure would be best for transfection studies in αT3-1 cells and in LβT2 cells. Although low 
luciferase values were obtained, no β-gal activity above background was detected, showing very low 
transfection efficiency.  This was found for both cell lines (αT3-1 cells and in LβT2 cells) although only 
the results for αT3-1 cells are shown in figure 12. 
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Secondly, the DEAE method was investigated. 
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Figure 13: The effect of the DEAE-dextran transfection method with varying amounts of wild type LG 
and β-gal expression vector on transfection efficiency. Amounts of 1, 0.5 or 0.25 µg wild type LG were 
used and amounts of 0.5, 0.25, or 0.125 µg β-gal expression construct were used. In the first column 
lipofectamine was used to compare with DEAE-dextran. Columns 2, 3 and 4 were transfected using 
DEAE-dextran with a cell density of 1x106 cells/well. Columns 5 and 6 were also transfected with 
DEAE-dextran but the cell density was 2x105 cells/well. Data was normalized by dividing the Luc 
values by β-gal values and plotted. Standard errors are shown and the graph is a result of combined 
results. This experiment was carried out 3 times in duplicate. 
 
Column 1 (lipofectamine) was compared to the rest of the columns (2-6 DEAE-dextran) in figure 13. 
There appears to be no difference in the transfection efficiency between the different columns (columns 
2-6). The transfection efficiency when one uses lipofectamine was significantly higher than when DEAE-
dextran was used (compare column 1 to the rest of the columns).  The absolute luciferase values that 
were obtained (in bars 2-6) were low (in the range of 0.46-0.67RLUs), which was similar to the PEI 
method. However the β-gal values were either erratic (in the range of 3.32-29.21RLUs) or could not be 
detected above background (in αT3-1 cells, graph not shown) showing that the DEAE-dextran method 
resulted in very low transfection efficiency although a slightly higher transfection efficiency than the PEI 
method was achieved. 
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In figure 13 there is a decrease in transfection efficiency when a lower cell density was used (compare 
columns 2 and 3 with 5 and 6).  Therefore, an investigation was undertaken to determine whether 
varying the cell densities could result in improved transfection efficiency when using DEAE-dextran and 
what effect the exposure time to chloroquine would have on the transfection efficiency (Figure 14).  
Exposure time to chloroquine was varied, as chloroquine is toxic to the cells, which may have 
contributed to the low β-gal values in the previous experiment. 
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αT3-1 cells:- Exposure time to chloroquine for 1 hour
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LβT2 cells- Exposure time to chloroquine for 30 minutes
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LβT2 cells:- Exposure time to chloroquine for 1 hour
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Figure 14: A comparison between LβT2 cells and αT3-1 cells using the DEAE-dextran method at 
varying cell densities and exposure time to chloroquine. The cell densities that were used were 1x105  
C 
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Figure 14 legend continuation: 
cells/well or 2x105 cells/well, which is indicated below the graph in brackets. The exposure time to 
chloroquine was 30 minutes or 1 hour, as indicated. The concentration of DEAE-dextran was also 
varied using 25, 12.5 or 50 µg/ml, respectively. Amounts of 1.0, 0.5 or 0.25 µg wild type LG were used  
together with 0.5, 0.25 or 0.125 µg β-gal expression vector. Data was normalized by dividing the 
luciferase values by the β-gal values. The graph is a result of combined data. Standard errors are 
shown and this experiment was performed twice in duplicate. 
 
In figure 14 it appears that for the αT3-1 cells there was no difference in the luciferase expression levels 
i.e. transcription efficiency when one varied cell density, exposure time to chloroquine or different 
concentrations of DNA when using the DEAE-dextran method. In the LβT2 cells a variation of luc/β-gal 
values can be seen when varying amounts of DNA were added.  Unfortunately, the RLU values were 
low and no positive control (Positive control = DNA with no promoter) was added therefore it was 
difficult to determine whether this was a variation due to transfection or just fluctuations in background. 
 
The results in figure 14 show low transfection efficiency (αT3-1 cells 30 min: luc ~0.4 RLUs, β-gal ~0.07 
RLUs 1 hr: luc ~0.4 RLUs, β-gal 0.08 RLUs. LβT2 cells 30 min: luc 0.4 RLUs, β-gal 0.8-9.2 RLUs 1 hr: 
luc ~0.6 RLUs, β-gal 7-26 RLUs), which could be due to the toxicity of chloroquine.  It appears that in 
LβT2 cells the transfection efficiency (luc/β-gal) is lower than in αT3-1 cells, which could be due to the 
sensitivity of the cells to DEAE-dextran. The luciferase values that were obtained were low and the β-
gal values were either erratic or low suggesting very low transfection efficiency. 
 
Next, LβT2 cells were transfected using the fugene method in order to see if an improvement of the 
transfection efficiency could be detected. Firstly, the optimal ratio of DNA: β-gal was determined. 
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Figure 15: The fugene method with varying ratios of LG: β-gal on transfection efficiencies in LβT2 cells. 
Amounts of 1 µg and 0.5 µg wild type LG were transfected together with 0.5, 0.1, 0.25, or 0.05 µg β-gal. 
The fugene: DNA ratio was 2:1.  Data was normalised by dividing the luciferase values by the β-gal 
values. The graph is a result of combined data.  Standard errors are shown and the experiments were 
carried out twice in duplicate. No DNA = just cells. PGL-2 basic vector = promoterless vector. The * and 
** represents the P value smaller than 0.05 (P<0.05) and 0.01 (P<0.01), respectively. 
 
This experiment was carried out in order to determine the optimal amounts and ratios of the wild type 
LG and β-gal plasmids in LβT2 cells. The transfection efficiency obtained with the fugene method (see 
figure 15) was as follows: background for luc was 0.0098 RLUs as compared to when DNA was present 
of 0.19 RLUs showing a clear difference. β-gal readings showed a clear difference of ~18 RLUs when 
no DNA was present to ~43 RLUs (Figure 15). When a comparison of the RLUs was made between the 
fugene method and the PEI, DEAE-dextran or lipofectamine method it showed that fugene was the 
method of choice since the luciferase values were significantly higher.   
 
From the results shown in figure 15 it was concluded that the optimal condition for future experiments 
was a 10 X difference between the LG: β-gal ratio.  From the above experiments the optimal condition 
to use was 1 μg LG and 0.1 μg β-gal. Further experimentation also suggested that using 0.5 μg LG 
together with 0.25 μg or 0.05 μg β-gal could also be used (data not shown). 
  
Fugene to DNA ratios were varied to determined whether a ratio of fugene: DNA could be obtained with 
an improved expression level of the GnRHR promoter-reporter construct. 1 μg LG and 0.5 μg β-gal was 
used to improve the expression level.  Varying amounts of fugene was used to determine if varying the 
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ratio of fugene to DNA/β-gal would improve the expression levels of the GnRHR promoter-reporter 
construct. 
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Figure 16: The effect of different fugene: DNA ratios on the transfection efficiency. LβT2 cells were 
used with a cell density of 2x105 cells/well. Ratios of 2:1 (fugene: DNA) and 1.5:1 (fugene: DNA) were 
used as indicated by the brackets. Varied amounts of wild type LG promoter constructs of 1, 0.5 or 
0.25 µg were used together with varied amounts of β-gal expression vectors of 0.5, 0.25 or 0.125 µg. 
Data were normalized by dividing the luciferase values by the β-gal values. The graph is a result of 
combined data. Standard errors are shown and the experiment was carried out twice in duplicate. No 
DNA = just contained cells. The ** represents the P value smaller than 0.01 (P<0.01). 
 
Figure 16 shows that the highest transfection efficiency was obtained with 1 µg luc and 0.5 µg β-gal for 
both ratios of fugene (2:1 ratio or 1.5: 1 ratio) in LβT2 cells. However, the 2:1 ratio of fugene had a 
lower random experimental error/variability than to the 1.5:1 ratio.  Therefore, a 2:1 ratio was used for 
further experiments. Thus far it is known that a 2:1 ratio of 1 µg luc and 0.5 µg β-gal resulted in the 
highest transcription efficiency and that one can use 1 µg LG/ 0.1 µg β-gal or 1 µg LG/ 0.5 µg β-gal.  
  
  
54
3.3 Preparation of mutated versions of the GnRH Receptor promoter-reporter construct 
To investigate the role of the -304/-296 and -336/-330 sites in basal and in induced expression of the 
mouse GnRHR promoter mutant constructs were prepared by PCR mutagenesis, where the SF-1-like 
site 3 (-304/-296) and the AP-1-like site (-336/-330) were mutated (see figure 17).  The template for 
site-directed PCR mutagenesis was an existing GnRHR promoter-reporter construct, which contained a 
GnRHR promoter fragment was cloned into the Bgl II site of the pGL2-basic vector (Pheiffer CP, 
Department of Biochemisty, University of Stellenbosch, Stellenbosch, 1998).  
 
 
 
A 
B 
  
  
55
 
 
C 
D 
E 
  
  
56
 
 
 
 
 
 
 
F 
G 
  
  
57
 
Figure 17: Schematic representation of site-directed PCR mutagenesis. A: pLG GnRHR promoter-
reporter receptor construct. As shown in A is the relative GL1 (sense) and GL2 (antisense) primers, 
which are pGL2-basic vector-specific primers.  Also indicated in A is mutated primer sense (MPA) and 
mutated primer antisense (MPS), which are overlapping primers containing the mutated sequence of 
interest. B: A detailed pLG GnRHR promoter reporter sequence together with the restriction enzyme 
digestion sites and the specific pGL2-basic vector-specific primers (GL1 and GL2).  C: Two separate 
PCR reactions are carried out which includes GL1 and MPA in one reaction and GL2 and MPS in the 
other reaction resulting in ~300 bp and ~400 bp PCR products, respectively. D: The fusion reaction 
process, which is performed with the two PCR reaction products from C, which contain an overlapping 
mutated site. GL1 and GL2 primers are also added to the fusion reaction.  The single smaller PCR 
product anneals at the overlapping mutated sites serving as the primer in the elongation step for the 
rest of the strand. E: The fusion reaction products from D are digested with restriction enzymes and gel 
purified. F: pLG is digested with the same restriction enzymes as used in E.  Two bands are observed 
on the low melting gel; the smaller band (E) is the wild type insert and the larger band (F) is the pGL2-
basic vector only.  The digested vector was further treated with calf intestinal alkaline phosphatase to 
remove any 5’ phosphate groups in order to prevent self ligation and gel purified.   G: after gel 
purification of the mutated insert (as shown in E) and vector only band (shown in F) the mutated insert 
and vector were ligated using T4 DNA ligase.  This ligated product (G) was transformed into E.coli 
MosBlue supercompetent cells and plated onto LB agar plates containing ampicillin and stored at 37°C.  
H: single colonies were picked and a screening process was carried out in the presence of GL1 and  
H 
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Figure 17 legend continuation: 
GL2 primers.   After colony screening the products of the PCR reactions were analysed using a 1% 
agarose gel to demonstrate the presence of the correct size of insert (~700bp).  For more detail see 
methods and materials.  (Diagram taken from Sadie’s PhD thesis, Department of Biochemistry, 
University of Stellenbosch, Stellenbosch).  
      
The mutant constructs used in these experiments were prepared with using site-directed PCR 
mutagenesis (see figure 17). These constructs were designated as pLGM3 or m3 and mAP-1, which 
are schematically shown in figure 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
wt (site 3): TGT CCT T 
m3: TGT TTT T 
wt (AP-1): TGA GTC A 
mAP-1: GGA ATT C 
 
Figure 18: Schematic representation of the different GnRH receptor promoter-luciferase constructs. 
The wild type construct of 600 bp of the GnRHR promoter upstream of the luciferase gene was 
previously cloned into pGL-2 basic vector (98) known as wild type LG (wt LG).  Constructs prepared 
from the wt LG construct but containing either a mutation in -304/-296 (i.e. m3) or a mutation in the -
336/-330 (i.e. mAP-1) were prepared and are illustrated schematically. The SF-1 site 1 located at -14/-
5, the SF-1 site 2  situated at -247/-236, the SF-1 site 3 situated at -304/-296 and the AP-1 site situated 
at position -336/-330 are shown, with the numbering all being relative to the ATG start codon. The  
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Figure 18 continuation: 
bases that differ between wild type and mutant constructs are shown below the diagram. Luc is 
representative of the luciferase reporter gene. 
 
Analytical agarose gel electrophoresis of plasmid preparations of the wild type and mutant constructs 
was performed (see figure 19).  The plasmid preparations of wild type and mutant constructs showed 
that mainly supercoiled DNA was obtained. These constructs were used for transfection studies in LβT2 
cells.  
                          
Figure 19: Analytical agarose electrophoresis of plasmids. Two different batches of the same construct 
were tested. Approximately 0.5-1 μg of each plasmid was loaded on a 1% agarose gel and run at 100 
V for 30 minutes-1 hour. Lanes 1 and 12 contain the DNA marker (Lambda DNA/Hind III) (Promega). 
Lanes 2 and 3 contain the wild type pLG construct (5.6 kb vector + 660 bp insert = 6.6 kb). Lanes 4 and 
5 contain the pSV-β-galactosidase (β-gal) construct (6.8 kb). Lanes 6 and 7 contain the pGL2-basic 
promoterless vector (Basic) (5.6 kb). Lanes 8 and 9 contain the pCMV-SF-1 construct (4.7 kb vector + 
2.1 kb SF-1 cDNA). Lanes 10 and 11 contain the pFC-PKA construct (7.18 kb). Lane 13 contains the 
site 3 mutant of the wild type promoter (5.6 kb vector + 660 bp insert = 6.6 kb). Lanes 14 and 15 
contains the activator protein-1 (AP-1) mutant of the wild type promoter (5.6 kb vector + 660 bp insert = 
6.6 kb). The marker in lanes 1 and 12 was loaded incorrectly; 5 μg was loaded instead of 0.5 μg.  
 
Lanes 2 and 3 in figure 19 contain the undigested GnRHR promoter construct, whereas lanes 13-15 
contain the undigested mutated versions. These plasmids were run before on an analytical agarose gel 
and are presumed to be of the correct size.  The positioning of the bands seems to correspond to the 
size of the plasmid by analysing them to each other.  The lowest band on the analytical agarose gel is 
known as supercoiled DNA.  Supercoiled pLG, m3 and mAP-1 plasmids migrate faster than the 
linearized plasmids (6.3 kb) because of their tightly wound structure.  For transfection studies 
supercoiled DNA is required for optimal transfection efficiency.  On the gel there are other bands 
present above the supercoiled bands, which are most likely, representative of linear or nicked circular 
plasmids.   
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-410 TTTCATTTTG    TATCTGTCTA   GTCACAACAG   TTTTTAGAAA      ACCTATTCAT 
-360 TAAGGCTAAT   TGGATGATAT  TATGAGTCAC    TTTCGACATC     AGAATTAGAC 
-310 TCCAAGTGTC   CTTCCTCACC  TACGATAAAA    AAGACGGGGC   ATCTGCTGAG 
-260 GGGCTACGGT  TACACTTGGC  CTTCAGGAGG   GCTTTGGCAT    GTTCTGTTAG 
-210 CACTCTTTTA    GATTATAAAG   GCCGAAAAAC   AAGTTTACCT     TGATCTTTCA 
-160 CGCCAAGTCC  AGAGTATCTT   GGGAAAAATA    AATTAGGCAG    AAATGCTAAC 
-110 CTGTGACGTT   TCCATCTAAA   GGAGGCAGAC   ATCAACAGCT    GCGCGTTCAG 
-60   TTATGATAAA    ACATCAGAAG  TAACAGGGAC    TCCACTCTTG 
-20   AAGCCTGTCC   TTGGAGAAAT  ATG 
 
Figure 20: The proximal mouse GnRH receptor promoter sequence. The two SF-1 sites (site 1 and site 
2) are in blue. A novel third SF-1-like site (site 3) is in red. The CRE is in purple, and the AP-1 site is in 
orange. Numbering of the sequence is relative to the translational start site. 
 
Once the mutations were complete the wild type pLG along with the mutants (m3 and mAP-1) were 
sequenced to make sure that a frame shift or deletions of certain bases had not occurred.  Alignment 
studies of the mutant constructs were carried out on the wild type GnRHR promoter sequence (see 
figure 20), which confirmed no sequence differences were present except for those desired mutated 
bases (alignments not shown). 
 
3.4 Site 3 and the AP-1 site are involved in the basal transcriptional regulation of 
the GnRHR promoter 
An investigation into the role of site 3 and the AP-1 site in the basal expression of the mouse GnRHR 
gene was carried out.  Mutated plasmids, prepared by either mutating site 3 or the AP-1 site, which are 
schematically shown in figure 18, were transfected into LβT2 cells and incubated overnight (16 hours). 
3.4.1 The involvement of site 3 on basal transcriptional levels of the GnRHR 
promoter 
Firstly, an investigation into the role of the SF-1-like site 3 on the GnRH receptor promoter in basal 
transcription in LβT2 cells was carried out. This was carried out in order to understand if site 3 played 
an important role in mediating the basal transcription levels of the GnRHR promoter gene.  Figure 21 
shows that mutating site 3 causes an increase in transcriptional activity of the GnRH receptor promoter 
by 1.5 fold (P<0.01). This increase in basal transcriptional levels indicates that site 3 plays an inhibitory 
role in the basal expression of the GnRH receptor promoter gene in LβT2 cells. 
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Figure 21: Role of site 3 at position -304/-296 (relative to the translational start site) on the basal 
transcriptional levels of the GnRHR promoter gene. LβT2 cells were transfected with wt LG or m3 both 
in the presence of the β-gal expression vector. Samples were transfected in triplicate. The graph is a 
result of combined data. Standard errors are shown and the experiment was carried out three times in 
triplicate. The ** represents the P value smaller than 0.01 (P<0.01) relative to wt LG. Fold induction is 
calculated by dividing the value obtained for m3 with that for wt LG.  
 
Previous research in our laboratory has shown that when a similar construct containing a  mutation in 
site 1 (pLGM1) (-15/-7 relative to the translation start site) was transfected into αT3-1 cells it showed 
the same basal activity as wt LG, showing that site 1 is not required for full basal activity of the GnRH 
receptor promoter 85. Previous studies on site 2 (-244/-236 relative to the translation start site) showed 
positive regulation of basal activity of the GnRHR promoter 14, 80 in αT3-1 cells.  In addition these 
researchers found that simultaneous mutations of both the SF-1 sites (site 1 and site 2) resulted in a 2-
fold decrease in the reporter gene expression when compared to the wt LG. These results in αT3-1 
cells suggests that the SF-1 sites 1 and 2 and SF-1 protein binding to these sites is important for the full 
basal expression of the GnRHR promoter in αT3-1 cells but that this protein can bind either to site 1 or 
to site 2 to maintain the basal levels and that when these sites are not available for binding that it 
results in a compromised basal expression 85.  
 
The increase in basal levels obtained in LβT2 cells when site 3 was mutated suggests that site 3 is 
involved in repressing the basal response of the GnRHR promoter in LβT2 cells; such that when it is 
mutated an inhibitory element is removed.  It is not known whether site 3 is involved with post-regulation 
of basal expression in LβT2 cells or if site 3 is involved in negative regulation in αT3-1 cells.  Future 
studies need to be carried out in order to determine if any differences that may be observed could 
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possibly be due to  cell-specific differences. It is evident that in both cell lines the SF-1 sites and their 
cognate proteins are important for basal expression levels but it is not known what the relative 
contribution of the different sites (1, 2 and 3) in each cell type is. 
3.4.2 The involvement of the AP-1 site in basal transcriptional regulation of the 
GnRHR promoter 
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Figure 22: The effect of an AP-1 mutation on the basal transcriptional levels of the GnRHR promoter-
reporter construct. LβT2 cells were transfected with either wt LG or mAP-1 both together with β-gal 
expression vector. The graph is a result of combined data.  Standard errors are shown and this 
experiment was carried out five times in triplicate. The ** represents the P value smaller than 0.01 
(P<0.01) relative to wt LG. 
 
From figure 22 it is evident that when the AP-1 site was mutated it resulted in a decrease in the basal 
transcriptional levels of the mouse GnRHR promoter. This is in line with research performed by Duval et 
al. (1997) 14 and White et al. (1999) 18 who reported that when the AP-1 site was mutated it resulted in 
approximately 58% decrease in basal transcriptional levels in αT3-1 cells. Maya-Nunez et al. (2003) 69 
also found similar results when mAP-1 of the mGnRHR promoter gene was transfected in GGH3 cells. 
 
In the above graph there is an approximately 50% decrease in basal transcriptional levels of the mouse 
GnRHR promoter in LβT2 cells. Therefore, the AP-1 site is involved in positively mediating the basal 
transcriptional response of the GnRHR promoter in LβT2 cells.  
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3.5 The effect of GnRH on the GnRHR promoter 
The aim was to investigate whether the proximal mouse GnRHR gene promoter responds to GnRH in a 
time- or dose-dependent fashion.  
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Figure 23: Time- and dose-response with GnRH on the GnRHR promoter construct in LβT2 cells. The 
wt LG construct was transfected into LβT2 cells using the fugene method followed by incubation for 24 
hours. The following day the medium was removed and the cells were stimulated with 100 nM, 1 μM or 
1 mM GnRH for 30 minutes, 8 hours and 16 hours. After the required times the cells were harvested 
and assayed. Data was normalized by dividing the luciferase values by the β-gal values. The graph is a 
result of combined data.  Standard errors are shown and the experiment was carried out in five 
independent experiments in triplicate. It is shown from the graph that the best dose- and time point is 
100 nM for 8 hours. 
 
In figure 23 when LβT2 cells were stimulated with GnRH with varying times and doses an increased 
expression at 100nM at 8 hours and 16 hours with the greatest increase at 100 nM at 8 hours was 
observed.  Cells that were stimulated for 30 minutes had no change in transcription of the GnRHR 
promoter. When cells were stimulated for 16 hours with 100 nM, 1 μM and 1 mM, a decrease in 
transcription was observed suggesting that the cells could be reverting to a negative feedback loop 
resulting in a decrease in the response of the cells to GnRH. What this means is that because GnRH is 
present for a lengthy period the transcription machinery starts switching off as it is over stimulated. It 
could also mean that for this period of 16 hours GnRH could be toxic resulting in cells dying.  
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3.5.1 Is site 3 involved in the GnRH regulation of the GnRHR promoter? 
Site 3 and the AP-1 site were investigated to see if they contributed in any way to the stimulatory effect 
of GnRH on transcription of the GnRH receptor gene in LβT2 cells. Results shown in figure 24, show 
the effect of stimulation of the wild type GnRHR promoter with 100 nM GnRH for 8 hours, which 
resulted in a 2.5 fold increase in transcriptional activity. Mutated site 3 was also transfected into LβT2 
cells without GnRH stimulation and resulted in a 1.5 fold increase in basal transcriptional levels as 
shown before in figure 21.   
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Figure 24: A representative graph of the role of site 3 in transcription of the GnRHR promoter in LβT2 
cells. The cells were stimulated either with or without 100 nM GnRH for 8 hours together with wt LG or 
mutated site 3 and the β-gal expression vector, before harvesting. The graph is a result of one 
representative out of three experiments. Standard errors are shown and this experiment was carried 
out three times in triplicate. The ** represents a P value of less than 0.01 (P<0.01), relative to the 
control (i.e. first bar). 
 
When cells containing the mutated site 3 construct were stimulated with 100 nM GnRH for 8 hours an 
increase in transcriptional levels of approximately 2.5 fold above basal levels (compare bars 1 and 2 to 
3 and 4) was observed. Therefore, the mutated site 3 construct retained a similar degree of 
responsiveness to GnRH as wt LG. Therefore, site 3 does not seem to be involved in the GnRH 
responsiveness of the GnRHR promoter.  Others have shown that the SF-1 site 2 is not involved in the 
GnRH response in αT3-1 cells 80.  This is in line with the findings for site 3, which is not involved in the 
GnRH response in LβT2 cells.   
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3.5.2 Is the AP-1 site involved in the GnRH regulation of the GnRHR promoter? 
The AP-1 site was investigated to see if it played a role in the GnRH responsiveness of the GnRHR 
promoter in LβT2 cells (Figure 25). Wt LG and a construct containing the mutated AP-1 site were 
stimulated with 100 nM GnRH and allowed to incubate for 8 hours before harvesting the cells with a 
lysis buffer. 
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Figure 25: A representative graph of the role of the AP-1 site in transcription of the GnRHR promoter 
in LβT2 cells. The cells were stimulated either with or without 100 nM GnRH for 8 hours together with 
wt LG or mutated AP-1 and the β-gal expression vector, before harvesting. The graph is a result of 
one representative out of five experiments. Standard errors are shown and this experiment was 
performed 5 times in triplicate. The ** represents a P value of less than 0.01 (P<0.01), relative to the 
control. 
 
When cells containing the wt LG promoter were stimulated with 100 nM GnRH an increased 
transcription of the GnRHR promoter of approximately 2.5 fold above basal levels (compare bars 1 and 
2) was observed. When the construct containing the mutated AP-1 site was transfected into LβT2 cells 
basal transcriptional levels decreased by 50%, although when stimulated with 100 nM GnRH this 
treatment increased transcriptional levels by approximately 2 fold (figure 25, compare bars 3 and 4). It 
appears that the fold increase in the expression levels caused by GnRH was similar for both wt LG and 
mAP-1 leading to the deduction that the AP-1 site is either not involved or has a minor effect on the 
GnRH-responsiveness of the GnRHR promoter. 
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Studies carried out on GnRH regulation are not always consistent between different cell lines or 
sometimes even in the same cell line. For instance some researchers observe an increase in GnRHR 
numbers in rat pituitary cells when stimulated with continuous administration of GnRH over several 
hours 86, whereas others observed no effect with continuous administration of GnRH but found an 
increase in GnRHR mRNA levels with pulsatile GnRH stimulation1.  What this means is that the method 
of administration affects the response. 
  
White et al. (1999) 18 found that when using a similar construct containing a mutated canonical AP-1 
element on the murine GnRHR promoter, a loss in GnRH responsiveness is obtained in αT3-1 cells.  
Ellsworth et al. (2003) 42 found that the induction of the murine GnRHR gene expression in αT3-1 cells 
was partially mediated by the same AP-1 site via the PKC pathway 42.  These researchers also found 
that when the AP-1 site was selectively removed in transgenic mice that it led to a loss of GnRH 
regulation of the murine GnRHR promoter. The problem with comparing these results found by 
Ellsworth et al. (2003) 42 in αT3-1 cells with those obtained in the present study in LβT2 cells is that the 
GnRHR appears to couple to different G-proteins in the two cell-lines, and hence activate different 
kinases, which may explain the different results. 
 
3.6 The effect of PKA on the GnRHR promoter; is site 3 and or the AP-1 site 
involved? 
An investigation into whether the activation of the PKA pathway regulated the GnRHR promoter gene in 
LβT2 cells was carried out together with the role of site 3 and or the AP-1 site in this activation. The 
PKA protein was over-expressed in LβT2 cells using transient transfections of an expression vector for 
PKA. Secondly, functional studies were carried out to provide functional evidence for the role of the SF-
1 protein as previous experiments suggested that both site 3 and the AP-1 site are involved in 
regulation of basal expression levels of the GnRHR promoter gene in LβT2 cells (See figure 21 and 22 
respectively). The strategy used was over-expressing the SF-1 protein using transient transfections of 
an expression vector for SF-1 protein to determine its involvement via site 3 or the AP-1 site.  
 
Site 3 and the AP-1 site were investigated to determine if these cis-elements contributed in any way to 
the stimulatory effect of the PKA pathway via the 600 bp of GnRH promoter region in LβT2 cells. 
GnRHR promoter constructs or mutated version thereof were transiently transfected in the presence of 
the PKA expression vector into LβT2 cells.  
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3.6.1 Is site 3 involved in the PKA response? 
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Figure 26: The effect of overexpression of PKA on the GnRHR promoter in LβT2 cells. The cells were 
co-transfected with 10 ng pFC-PKA with either wt LG or m3 together with the β-gal expression vector 
and incubated overnight, before harvesting. Due to the standard errors there appears to be no 
statistically significance between LG/β-gal/Basic and LG/β-gal/PKA and no statistically significance 
between m3/β-gal/Basic and m3/β-gal/PKA. Standard errors are shown. Results of one experiment are 
shown above.  This experiment was repeated five times in triplicate and the same trend was observed 
for all experiments. ** represents a P value of less than 0.01 (P<0.01), relative to the control. 
 
Over-expression of the PKA protein resulted in an increase in the activity of wt LG promoter of 
approximately 1.5 fold over cells that were not co-transfected with PKA (Figure 26) indicating that PKA 
is involved in positive regulation of the GnRHR promoter. When the mutated site 3 construct was 
transfected into LβT2 cells and over-expressed with the PKA protein a slight difference was observed.  
Wt LG together with PKA resulted in a ~2-fold increase over basal levels (see bars 1 and 2) of the 
GnRHR promoter in LβT2 cells. The mutated site 3 construct resulted in a ~ 1.2 fold increase over 
basal levels (compare bars 3 and 4) of the wt LG promoter in LβT2 cells.  This suggests that site 3 is 
partially involved in the PKA response although it is not absolutely required for the response. There is 
no evidence that PKA was produced in transfected cells although it could have been confirmed by 
performing Western blots. 
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3.6.2 Is the AP-1 site involved in the PKA response? 
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Figure 27: The effect of PKA on the GnRHR promoter in LβT2 cells. The cells were co-transfected with 
10 ng pFC-PKA with either wt LG or the mutated AP-1 site construct together with the β-gal expression 
vector and incubated overnight, before harvesting. Due to the standard errors there appears to be no 
statistically significance between LG/β-gal/Basic and LG/β-gal/PKA and no statistically significance 
between mAP-1/β-gal/Basic and mAP-1/β-gal/PKA. The graph is a result of combined data.  This 
experiment was repeated four times in duplicate.  
 
According to figure 27, there appears to be a slight decrease in the PKA response when compared to 
the wt LG, unlike the increase observed in figure 26. The mutant AP-1 basal responsiveness has the 
same trend as seen in figure 22 showing a ~50% decrease in the basal transcriptional levels. From 
figure 27 it is difficult to conclude if the AP-1 site is involved in the PKA response. The small changes 
observed were not statistically significantly different to each other, most likely since the small effect was 
within the range of the experimental error and variable.  It is thus possible that in this system the AP-1 
site is involved in mediating a small PKA response, as found by Lin et al. (1999) 34 in GGH3 cells where 
GnRH activation of the rat GnRHR promoter occurred via cAMP and protein kinase A pathways.  
However due to the high degree of variability in the response in the current system, the results were 
inconclusive.  
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3.7 The role of site 3 and or AP-1 sites in the SF-1 response 
An investigation to determine whether over-expressing the SF-1 protein regulates the GnRHR promoter 
gene in LβT2 cells was carried out together with the role of site 3 and the AP-1 site. The SF-1 protein 
was over-expressed in LβT2 cells using transient transfections of an expression vector for SF-1. 
Secondly, functional studies were carried out to provide functional evidence for the role of the SF-1 
protein, since previous experiments suggested that site 3 and the AP-1 site were both involved in 
regulating basal levels of expression of the GnRHR promoter gene in LβT2 cells (See figure 21 and 22 
respectively). The effect of the SF-1 protein on the AP-1 site was carried out in order to determine if 
there was any form of cross-talk between the AP-1 site and the SF-1 site, which was speculated by 
some researchers 87. 
3.7.1 Is site 3 involved in the SF-1 response? 
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Figure 28: Representative graph showing the effect of over-expressed pCMV-SF-1 on wt LG and m3. 
20 ng pCMV-SF-1 was co-transfected with 100 ng wt LG and 10 ng pSV-β-gal expression construct into 
LβT2 cells and cells were incubated overnight. The graph above is from one representative experiment.  
Standard errors are shown. This experiment was repeated three times in triplicate and the same trend 
was observed for all experiments. The * and *** represents a P value of 0.05 (P<0.05) and 0.001 
(P<0.001), relative to the control, respectively.   
 
As shown in figure 28, the presence of 20 ng pCMV-SF-1 increased pLG activity by 4-fold (compare 
bars 1 and 2). This was expected as the GnRHR promoter contains 2 known SF-1-like sites and a third 
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putative SF-1 site (site 3), which was being investigated. When site 3 was mutated a 3-fold increase in 
basal expression relative to the pLG construct was observed, similar to the result shown in figure 21. 
Unlike the result with the wt construct when site 3 was mutated in the presence of the SF-1 expression 
vector resulted in a decrease in the expression levels as compared to mutated site 3 construct in the 
absence of the SF-1 expression vector (compare bars 3 with 4).  The loss of the positive response to 
over-expression of the SF-1 protein seen with the wt construct, after mutation of site 3, strongly suggest 
that site 3 is required for mediating a positive response to SF-1 protein.  
 
Other researchers found that when site 2 (-244/-236 NRS) was mutated in αT3-1 cells a complete loss 
in the SF-1-induced increased in expression levels seen with the wt construct was observed 80.  
However, mutation of site 1 (-15/-7 NRS) did not result in a loss of the increase in expression levels 
obtained in αT3-1 cells in the presence of over-expressed with SF-1 80.  Therefore, it can be said that 
the SF-1-like site 2 is an important site for mediating stimulatory effects of SF-1 protein on the 
expression levels of the GnRHR promoter gene in αT3-1 cells.  A comparison between site 3 and site 2 
shows that the differences between these two sites are 2 base pairs (7/9 bases are identical), 
suggesting that the same factors bind at these two sites. 
 
Thus, site 2 is required for mediating the response to SF-1 protein in αT3-1 cells whereas site 3 is 
required for mediating the response to SF-1 protein in LβT2 cells.  These different results in the two cell 
lines could be due to cell specific differences in the signalling pathways.  Alternatively, there is a 
possibility that both these sites are required to be intact in both cell lines although this has not yet been 
tested.  Further studies could lead us to a deeper understanding about the role of these two sites in two 
cell lines. 
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3.7.2 Is the AP-1 site involved in the SF-1 response? 
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Figure 29: Representative graph showing the effect of over-expressed SF-1 on wt LG and on the mAP-
1 site. 20 ng pCMV-SF-1 was co-transfected with 100 ng wt LG and 10 ng pSV-β-gal expression 
construct into LβT2 cells and the cells were incubated overnight. The graph above is a result of one 
representative experiment. Standard errors are shown. This experiment was repeated three times in 
triplicate and the same trend was observed for all experiments. There was no statistical significance 
when comparing bars 1 and 2 and comparing bars 3 and 4. 
 
Figure 29, showed no increase in the expression levels between wt LG in the presence of the pCMV-
SF-1 expression vector as compared to in the absence of the pCMV-SF-1 expression vector, unlike the 
effects seen in figure 28.  Thus it was not possible to determine whether the AP-1 site was involved in 
mediating the SF-1 response due to the high degree of variability in the response of the cells.   
 
3.8 The GnRHR promoter is regulated by dexamethasone 
An important question that was asked was whether dexamethasone (dex) regulates the GnRHR 
promoter gene in LβT2 cells and if so, which sites are important for this regulation in LβT2 cells. 
Researchers such as Maya Nunez et al. (2003) 69 (in GGH3 cells) and Turgeon et al. (1996) 43 (LβT2 
cells) found that the GnRHR promoter was responsive to the synthetic glucocorticoid, dex in the 
respective cell lines mentioned.  In the present study, LβT2 cells were transfected with pLG and 
incubated overnight. The next day the cells were stimulated with different concentrations of dex (10, 
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100 and 1000 nM) for varying times (30 minutes, 4, 8 and 16 hours). The cells were then harvested and 
assayed for expression levels (see figure 30).  
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Figure 30: A time and dose response of wild type GnRHR reporter gene to dex. LβT2 cells were 
transfected with 100 ng wt LG together with a 10 ng pSV-β-gal expression vector and incubated with 
different concentrations of dex (10 nM, 100 nM, 1 μM, respectively) and varying time points (30 
minutes, 4 hours, 8 hours and 16 hours). The control for this experiment was 0.1% ethanol for each 
time point. Cells were then harvested depending on their time point. The graph is a result of combined 
data. Standard error bars are shown and this experiment was carried out four times in triplicate.  
 
Figure 30 shows that the GnRHR promoter-reporter construct in LβT2 cells responds positively to dex. 
Between all time points the basal levels of the wt LG increases, most likely due to cell growth effects. At 
30 minutes and at 4 hours there appears to be a slight response at the higher concentration of dex. At 8 
hours there is an increase with 10 and 100 nM and a further increase when 1 μM dex is added. The 
greatest increase was observed at 16 hours with 1 μM dex, which is consistent with results obtained in 
GGH3 cells 69.  These researchers also found that if GGH3 cells were further stimulated for up to 24 
hours that there is a decrease in the response 69. It would be interesting to see if they were stimulated 
for longer than 16 hours, which will be the subject of future studies. 
3.8.1 Is site 3 involved in the dexamethasone response of the GnRHR promoter? 
An investigation was performed to determine which cis-elements on the GnRHR promoter are important 
for the positive regulation found when stimulated with dex. Constructs used for these experiments 
contained either the wt LG or those in which site 3 or the AP-1 site on the GnRHR promoter were 
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mutated. The constructs were transfected into LβT2 cells together with the pSV-β-gal expression vector 
and the cells were incubated overnight. The next day the cells were stimulated with 1μM dex for 16 
hours before being harvested and assayed.  
 
As one can see from figure 31 when cells were stimulated with dex it resulted in a 1.5-fold increase in 
reporter expression over uninduced wt LG, which is similar to results shown in figure 30. Mutation of 
site 3 (plasmid m3) resulted in a ~6 fold increase of basal levels over the wt LG control. The increase 
shown in figure 31 is greater than that shown in figure 21, reflecting the high degree of variability of the 
response of the cells.  When m3 was stimulated with 1 μM dex a loss of the dex response was 
observed when compared with the increase seen with wt LG when stimulated with dex. This result 
suggests that site 3 is required for the dex response. 
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Figure 31: A representative graph showing the role of site 3 in the response to dex on the GnRHR 
promoter in LβT2 cells. 100 ng wt LG or 100 ng m3 were transfected into LβT2 cells together with 10 ng 
of β-gal expression vector and cells were stimulated either with or without 1 μM dex and incubated for 
16 hours, before harvesting. The graph shows the result of one representative experiment.  Standard 
errors are shown and this experiment was carried out three times in triplicate. The * represents a P 
value of less than 0.05 (P< 0.05), relative to the control (bar 1).  
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3.8.2 Is the AP-1 site involved in the dexamethasone response of the GnRHR 
promoter? 
The AP-1 site was investigated to determine if it had a significant role in the positive regulation of the 
GnRHR promoter by dex. 
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Figure 32: A representative graph showing the role of the AP-1 site in the response to dex on the 
GnRHR promoter in LβT2 cells. 100 ng wt LG or 100 ng mAP-1 were transfected into LβT2 cells 
together with 10 ng of β-gal expression vector and cells were stimulated either with or without 1 μM dex 
and incubated for 16 hours, before harvesting. The graph shows the result of one representative 
experiment. Standard errors are shown and this experiment was carried out three times in triplicate. 
The ** represents a P value of less than 0.01 (P< 0.01), relative to the control. 
 
As shown in figure 32, wt LG expression was stimulated with 1 μM Dex showing a 2.5-fold increase. 
When the AP-1 site was mutated it caused a 50% decrease in basal transcriptional activity, which is in 
line with what was shown in figure 22. Mutation of the AP-1 site resulted in complete loss of the dex 
response when stimulated with 1 μM dex. These results show that the AP-1 site is required for the 
positive regulation of the GnRHR promoter by dex in the LβT2 cells. Maya-Nunez et al. (2003) 69 found 
the same results in GGH3 cells as we found in LβT2 cells suggesting that the effect seen with dex is not 
cell specific.  
 
  
  
75
It can be said from these studies that site 3 and the AP-1 site play a significant role in mediating the 
dexamethasone response of the GnRHR promoter in LβT2 cells.  The result for AP-1 has not been 
previously found by others in this specific cell line while no other investigators have previously 
investigated the role of site 3.  
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Conclusion 
 
The mouse GnRH receptor (mGnRHR) promoter contains two established SF-1 DNA binding sites 
located at positions –244/-236 and –15/-7 relative to the translational start site and a third putative SF-1 
binding site (site 3) with unknown function located at position –304/-296.  In this study the role of the 
SF-1 site 3 and the AP-1 site (-336/-330) in the transcriptional regulation of the mGnRHR promoter in 
LβT2 cells was investigated.  
An overview of the finding results are given below in the table. 
 
 wt LG Site 3 AP-1 site 
GnRH Yes No No 
Overexpressed 
SF-1 
Yes Yes ND 
Overexpressed 
PKA 
Yes Partial ND 
Dexamethasone Yes Yes Yes 
 
Table 2: An overview to the results obtained with regards to the mGnRHR promoter activity being 
increased in LβT2 cells. “Yes” indicates where cis elements are involved. “No” indicates where cis 
elements are not involved. Partial indicates where cis elements are partially involved. “ND” indicates not 
determined and requires further experimentation. 
 
Earlier studies performed on site 1 of the mGnRHR promoter found that site 1 was not important in the 
mediation of basal levels  80 in αT3-1 cells.  However a positive role for site 2 of the mGnRHR promoter 
in mediating basal expression levels in αT3-1 cells was previously established 14, 80. Experiments 
carried out with site 3 on the mGnRHR promoter showed that site 3 is involved in basal regulation. 
Findings were that when site 3 was mutated it resulted in a 1.5 fold increase over wt LG, which 
suggests that site 3 acts as an inhibitory element in LβT2 cells (see figure 33). 
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Figure 33: A schematic diagram showing an increase in basal levels when site 3 was mutated on the 
GnRHR promoter in LβT2 cells. A = negative inhibitor. This diagram is supported by figure 21. 
 
It was also evident that the AP-1 site is involved in the basal levels of mGnRHR promoter activity in 
LβT2 cells.  When the AP-1 site was mutated it resulted in a 50% decrease in basal transcriptional 
levels suggesting that the AP-1 site acts as a stimulatory element in LβT2 cells, possibly via binding of 
a stimulatory protein.  The findings for the AP-1 site are in line with other researchers in GGH3 cells 69 
and in αT3-1 cells 14, 18. One can conclude from this that the AP-1 site on the mGnRHR promoter is 
important in basal transcriptional levels in several pituitary cell lines. 
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Figure 34: A schematic diagram showing a decrease in basal levels when the AP-1 site is mutated on 
the GnRHR promoter in LβT2 cells. B = positive regulator. This diagram is supported by figure 22. 
 
The role of the AP-1 site and site 3 was investigated with regards to the upregulation of the wild type 
mGnRHR promoter when stimulated with GnRH in LβT2 cells.  It has been previously shown that the 
AP-1 site is required to mediate a GnRH-mediated upregulation in αT3-1 cells 18.  In contrast to these 
researchers the findings in this study were that the AP-1 site is not involved in the GnRH response of 
the GnRHR promoter in LβT2 cells. Site 3 was not involved either in the GnRH response in LβT2 cells. 
This could be due to cell specific differences between LβT2 cells and αT3-1 cells. For example it is 
possible that a GnRH response is mediated by different cis elements in LβT2 cells. The type of 
stimulation (continuous versus pulsatile) in LβT2 cells could also affect the type of response that is 
observed.  There is currently much controversy as to which type of stimulation gives the optimum 
results.  In this study continuous administration of GnRH was performed, which is suggested by Kaiser 
et al. (1997) 1  to result in a maximum of 2-fold increase as opposed to much higher values in primary 
pituitary cells. From the literature it is known that GnRH does play a role in the transcription of the 
mGnRHR promoter leading to PKA activating CREB and that GnRH activates the PKA pathway via the 
Gs pathway in LβT2 cells, therefore one could speculate that GnRH acts via CREB. 
 
AP-1 site 
B 
AP-1 site mutated 
B
Decrease in basal transcription as the positive regulator 
cannot bind to the AP-1 site. 
wt LG 
Mutated AP-1 site 
  
  
79
In this study the PKA response was difficult to study due to various factors affecting the experiment. 
These reasons are as follows: a high degree of variability in the responses, time of day the experiment 
was carried out, the passage number of the cells, contamination of media used, or the temperature of 
media used. In these studies it was not possible to show whether the AP-1 or the SF-1 site on the 
mGnRHR promoter was involved in the PKA response in LβT2 cells, since only a small non-
reproducible effect was observed with PKA.  
 
Site 3 of the mGnRHR promoter gene binds the SF-1 protein from nuclear extracts of LβT2 cells in 
vitro. When site 3 was mutated a complete loss in the SF-1 response was observed in LβT2 cells.  This 
is interesting as no experiments have been performed on this site before and the role of this site was 
thus previously unknown. A role for site 3 in mediating the increase in transcription by SF-1 in line with 
the roles of two other established SF-1 sites 80. 
  
Lastly, whether the mGnRHR promoter was responsive to a synthetic glucocorticoid, dexamethasone in 
LβT2 cells was investigated.  It was shown that dex up-regulates the mGnRHR promoter in LβT2 cells 
and that this response requires site 3 as well as the AP-1 site, since the mutation of either one of these 
sites resulted in a loss of the dex response.  It is known from experiments above that in the absence of 
dex or GnRH that something binds to the AP-1 site in vitro and it has been shown that the proteins that 
do bind to the AP-1 site do not include c-Fos.  At present it is not known what binds to the AP-1 site in 
the presence of GnRH and Dex. 
 
A possible model is described in figure 35 showing the two different pathways that can be involved in 
the stimulation of the GnRHR promoter when dexamethasone is present. 
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Figure 35: Schematic representation of the effect of the presence or absence of dexamethasone on the 
AP-1 site and site 3 on the mGnRHR promoter in LβT2 cells. A = no dex. When no dex is present c-jun 
homodimers bind to the AP-1 site resulting in transcription of GnRHR promoter. 
B = Two scenarios for the presence of dex. B(1) In the presence of dex the GR binds to an “unknown” 
GRE in close proximity to the AP-1 site, the c-jun homodimer binds to the AP-1 site and the SF-1 
protein binds to the SF-1 site.  All three proteins interact with DNA causing a looping out effect.  A 
greater increase in transcription of the mGnRHR promoter is observed as compared to when no dex is 
present.  B(2) The same effect is observed for B(2) as in B(1), when dex is present, but in this model 
GR does not bind to the DNA, it directly interacts and binds with the AP-1 c-jun homodimer resulting in 
a greater transcriptional increase of the mGnRHR promoter as compared to when no dex was present.  
Diagram by Fernandes (2006). 
 
From experiments shown earlier (see figure 10) the data suggests that under basal conditions c-Fos 
does not bind to the AP-1 site leading to the speculation that c-Jun binds as a homodimer to the AP-1 
site on the mGnRHR promoter in LβT2 cells. Research performed by others suggested that when 
GnRH was present an increase in the c-fos protein was observed, increasing the possibility that the AP-
1 protein would bind to the AP-1 site as a heterodimer. Another possibility is that on the mGnRHR 
promoter there is a non-classical GRE site ~21bp from the AP-1 site. Literature suggests that if a GRE 
and AP-1 binding site overlap and the AP-1 site is occupied by c-jun homodimer and the GRE is 
occupied by the liganded GR then it results in an increase in transcription of the mGnRHR promoter or 
alternatively a decrease in transcription of the mGnRHR promoter if both c-Jun and c-Fos is present. In 
order for transactivation or transrepression to occur by binding of the GR and the AP-1 proteins to the 
GRE-AP-1 site the GRE-AP-1 site must be 26bp or greater apart to transactivate or 14-18bp apart to 
transactivate or transrepress 67 in the presence of dex.  
 
The results obtained in this study would be consistent with a model whereby a non-classical GRE 
occurs in the murine GnRHR promoter which partially overlaps with the AP-1 site. Therefore, when the 
AP-1 site is mutated a loss in transcription of the mGnRHR promoter is observed when dex is present. 
 
A possible interpretation of the result for site 3 where a decrease in transcription was observed when 
site 3 was mutated, transfected into LβT2 cells and stimulated with dex could possibly be that when 
LβT2 cells were stimulated with dex an increase in SF-1 protein occurred, which cannot bind to the SF-
1 site (since site 3 is mutated) resulting in a decrease in transcription of the mGnRHR promoter, 
although no studies have been carried out on this speculation. Another possible speculation is that site 
3 is in close proximity to the AP-1 site and that cross-talk could occur between these two sites. For a full 
transcriptional response of the mGnRHR promoter to occur when stimulated with dex both sites are 
required to be present on the mGnRHR promoter resulting in the increase in transcription of the 
mGnRHR promoter.  If one of the sites were mutated the transcriptional activity of the mGnRHR 
promoter was compromised.  The mutation of both site 3 and the AP-1 site on the mGnRHR promoter 
has not yet been carried out in the presence of dex and it would be interesting to see if a response even 
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if minimal (due to other SF-1 sites being present) is still observed or if a complete loss in the dex 
response would occur. 
 
Figure 36: Schematic diagram showing a possible model of how the glucocorticoid receptor responds 
to dex causing increases in SF-1 protein levels which then results in increased binding of SF-1 protein 
to site 3 in the murine GnRHR promoter and increased transcription thereof. This diagram is supported 
by figure 31. 
 
The experimentations carried out in this thesis were designed to gain insight into the relationship 
between stress and reproduction.  The findings were very interesting in that an increase in transcription 
of the mGnRHR promoter in LβT2 cells was seen after 16 hours of stimulation with dex, while no 
increase was observed at 30 min or at 4 hr, similar to the results of Maya-Nunez et al. (2003) 69.  Maya-
Nunez et al. (2003) 69 also found that when cells were stimulated for longer than 16 hours with dex that 
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a decrease in transcription of the GnRHR promoter in GGH3 cells was observed.  It is well established 
that chronic stress results in a decrease in reproduction. However, the effects of short term stress on 
reproduction are not well understood. The findings in this study suggest that when woman are mildly 
stressed an increase in reproduction can occur, that may be mediated via an increase in GnRHR levels, 
with a resulting increase in sensitivity to GnRH in the pituitary. These findings support the literature 
mentioned earlier where it was suggested that under some conditions that stress can have a positive 
effect on reproduction, and suggest a possible mechanism for this effect  69. 
 
 
Future studies 
 
Results presented in this thesis have raised many interesting questions for future studies. The following 
list described below gives examples of some of the questions that have been raised to be investigated 
for future studies. 
• Whether the proteins that bind to site 3 and the AP-1 site are required to interact for different 
responses requires further experimentation.  
• In particular, the effects of dexamethasone on site 3 need to be further investigated to 
determine whether the response requires cross-talk between proteins binding to site 3 and the 
AP-1 site.  This could be further investigated by performing simultaneous mutations of both 
sites.   
• Further experiments are required to determine whether indirect effects play a role in the dex 
response such as whether dex results in an increase in SF-1 protein expression levels.  
• Whether c-Jun binds to the AP-1 site as a homodimer under certain circumstances, while c-
Fos and c-Jun bind as a heterodimer under others needs to be investigated.  
• The details of the kinase pathway involved in regulating the AP-1 site and site 3 need to be 
further investigated to understand whether the PKC pathway is largely responsible in the 
regulation of these sites or whether other kinase pathways also play a role such as the PKA 
pathway.  
• It would also be interesting to investigate whether any other cis elements mediate the dex 
response such as possible non-classical GREs.  
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 Addendum A 
 
6.1 Preparation of the Solutions 
6.1.1 TE buffer (pH 8) 
10 mM Tris.HCl (pH8) 
1 mM EDTA (pH8) 
 
6.1.2 Luria-Bertani (LB) Medium 
10 g Tryptone 
5 g yeast extract 
10 g Sodium Chloride 
Mixture is made up to 1 L with de-ionized water 
Autoclave to sterilize. 
6.1.3 SOC Medium 
20 g Tryptone 
5 g Yeast tryptone 
0.5 g Sodium Choloride 
Mixture is made up to 1L with deionized water. 
10ml of a 250 mM solution KCl was added to the above. The pH was adjusted to 7.0 with NaOH. The 
volume was then adjusted to 1 L. The mixture was then sterilized by autoclaving. Before use 5 ml sterile 
2M MgCL2 and 20 ml sterile 1 M solution of glucose was added to the mixture. The mixture was then 
aliquoted and stored at -20°C. 
 
6.1.4 50x TAE 
242 g Tris Base 
57.1 ml Glacial acetic acid 
100 ml 0.5 M EDTA (pH 8) 
Make up to 1 L using de-ionized water. 
6.2 Gel mobility shift assays 
6.2.1 5% acrylamide gel mixture 
6.6  ml Acrylamide solution (29:1 molar ratio of acrylamide to bisacrylamide.) 
32.5 ml Sterile deionized Water 
400 μl 50 x TAE 
400 μl 10% (w/v) Ammonium Persulphate (APS) (BDH AnalaR) 
70 μl TEMED (Merck) 
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ADDENDUM B 
PLASMID MAPS 
 
B1: pGL2-Basic vector map and multiple cloning site sequence 
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B2: pSV-β-Galactosidase expression vector  
 
 
 
 
 
 
 
B3: pFC-PKA: 
No map was available for this construct. Technical information from Stratagene was 
as follows: 
Size: 7180 bp 
Restriction pattern: HindIII, XbaI, XhoI: 480 bp, 500 bp, 1200 bp, 5000 bp 
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B4: Other vector backbones used for expression constructs 
E5.1 pCMV5 (i.e. SF-1) 
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